胰腺癌临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 1 药物

clinicaltrials.gov NCT05403554

A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers

适用疾病: Epithelial Ovarian Cancer；Triple Negative Breast Cancer；Non-squamous Non-small-cell Lung Cancer
干预: Biological NI-1801，NI-1801 in combination with anti-PD1 (Pembrolizumab)，NI-1801 in combination with paclitaxel，Paclitaxel
地点: France，Italy
申办方: Light Chain Bioscience - Novimmune SA

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT04657068

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

适用疾病: Advanced Cancer；Metastatic Cancer；Ovarian Cancer
干预: ART0380，Gemcitabine，Irinotecan
地点: United States，France，Spain，United Kingdom
申办方: Artios Pharma Ltd

即将招募 Phase 3 药物

clinicaltrials.gov NCT07620574

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

适用疾病: Cancer；Renal Cell Carcinoma (RCC)；Pancreatic Neuroendocrine Tumors (pNET)
干预: Cabozantinib，Zanzalintinib，Atezolizumab，Nivolumab
地点: 未列出
申办方: Exelixis

正在招募 Phase 2 药物

clinicaltrials.gov NCT06813079

Using Tumor Models to Determine Treatments

适用疾病: Pancreatic Ductal Carcinoma；Advanced Cancer；Epithelial Tumor
干预: Cobimetinib，Ponatinib，Brigatinib，Colchicine
地点: Canada
申办方: University Health Network, Toronto

即将招募阶段未标明药物

clinicaltrials.gov NCT07592819

A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)

适用疾病: Pancreas Adenocarcinoma (MSI-H)；Pancreatic Cancer Resectable
干预: mFOLFIRINOX (modified FOLFIRINOX)
地点: 未列出
申办方: Institut Paoli-Calmettes

正在招募 Phase 1 药物

clinicaltrials.gov NCT04361708

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

适用疾病: Pancreatic Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma；Adenocarcinoma
干预: Oxaliplatin，Docetaxel，Leucovorin，Irinotecan
地点: United States
申办方: University of Chicago

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06910657

IDOV-Immune for Advanced Solid Tumors

适用疾病: Colorectal Cancer；Pancreatic Cancer；Melanoma
干预: IDOV-Immune (oncolytic vaccinia virus)
地点: United States，Australia
申办方: ViroMissile, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06892054

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

适用疾病: Pancreatic Adenocarcinoma
干预: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
地点: France，Spain
申办方: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

即将招募阶段未标明手术/操作

clinicaltrials.gov NCT07547033

Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

适用疾病: Pancreatic Adenocarcinoma；Pancreatic Head Cancer
干预: SMA-first pancreaticoduodenectomy using either right posterior or anterior approach. SMA identified and isolated with peri-adventitial dissection before any irreversible section.，Conventional pancreaticoduodenectomy without prior isolation of the SMA; antero-posterior approach of the uncinate process after pancreatic section.
地点: France
申办方: Assistance Publique - Hôpitaux de Paris

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT07328607

Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy

适用疾病: Pancreatic Ductal Adenocarcinoma；Ampullary Carcinoma；Distal Cholangiocarcinoma
干预: Open Pancreaticoduodenectomy，Laparoscopic Pancreaticoduodenectomy
地点: Egypt
申办方: Minia University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05218889

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer；PDAC - Pancreatic Ductal Adenocarcinoma；Pancreas Cancer
干预: surufatinib + camrelizumab + nab-paclitaxel + S-1，nab-paclitaxel + gemcitabine
地点: China
申办方: Chinese PLA General Hospital

正在招募 Phase 2 手术/操作

clinicaltrials.gov NCT05984810

NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101

适用疾病: Pancreas Adenocarcinoma
干预: Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
地点: Netherlands
申办方: Leiden University Medical Center

正在招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT05076760

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

适用疾病: Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MEM-288 Intratumoral Injection，Nivolumab，Docetaxel
地点: United States
申办方: Memgen, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07227168

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

适用疾病: Head and Neck Squamous Cell Carcinoma HNSCC；Non-Small Cell Lung Cancer NSCLC；Esophageal Cancer
干预: STRO-004，Pembrolizumab
地点: United States
申办方: Sutro Biopharma, Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT04421820

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

适用疾病: Colorectal Cancer；Pancreatic Cancer；Gastric Cancers
干预: BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)，BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
地点: United States，Canada，Germany，Ireland 等 3 个
申办方: Bold Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07020221

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

适用疾病: Pancreatic Ductal Adenocarcinoma；Non Small Cell Lung Cancer；Colorectal Cancer
干预: VS-7375，Cetuximab，Carboplatin + Pemetrexed + Pembrolizumab，Gemcitabine
地点: United States，Australia
申办方: Verastem, Inc.

正在招募 Phase 1 器械药物

clinicaltrials.gov NCT05723107

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

适用疾病: Pancreatic Cancer
干预: Chemotherapy，Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)
地点: United States
申办方: NYU Langone Health

正在招募 Phase 2 药物

clinicaltrials.gov NCT06825546

Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma

适用疾病: Advanced Pancreatic Ductal Adenocarcinoma
干预: Icaritin，AG chemotherapy
地点: China
申办方: Sir Run Run Shaw Hospital

即将招募 Phase 2 药物

clinicaltrials.gov NCT07233850

A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

适用疾病: Gastric/Gastroesophageal Junction Adenocarcinoma；Metastatic Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: SSGJ-706+XELOX，SSGJ-706+Bevacizumab+XELOX，SSGJ-706+AG，SSGJ-706+TP
地点: China
申办方: Shenyang Sunshine Pharmaceutical Co., LTD.

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07410494

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

适用疾病: Cancer；Breast Cancer；Non-Small Cell Lung Cancer (NSCLC)
干预: EB-SELECT Single-Target CAR-NK Cells，Dual-Target Antigen-Selected CAR-NK
地点: China
申办方: Essen Biotech

正在招募 Phase 1 药物

clinicaltrials.gov NCT07349537

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Adenocarcinoma
干预: RMC-5127，daraxonrasib，cetuximab
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06128551

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

适用疾病: Non-Small Cell Lung Cancer (NSCLC)；Colorectal Cancer；Pancreatic Ductal Adenocarcinoma
干预: Elironrasib，Daraxonrasib
地点: United States，France，Germany，Italy 等 3 个
申办方: Revolution Medicines, Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05985655

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

适用疾病: Head and Neck Squamous Cell Carcinoma (HNSCC)；Pancreatic Adenocarcinoma；Non-small Cell Lung Cancer (NSCLC)
干预: GTAEXS617，SoC
地点: United States，Belgium，United Kingdom
申办方: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07213791

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

适用疾病: Ovarian Neoplasms；Breast Neoplasms；Pancreatic Intraductal Neoplasms
干预: LY4337713
地点: United States，China，Germany，Japan 等 1 个
申办方: Eli Lilly and Company

正在招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT02598349

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

适用疾病: Pancreatic Cancer
干预: Proton Radiation，Capecitabine，Surgical resection
地点: United States
申办方: Proton Collaborative Group

正在招募 Phase 2 药物手术/操作放疗

clinicaltrials.gov NCT05083247

Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

适用疾病: Pancreatic Neoplasm；Pancreatic Adenocarcinoma；Borderline Resectable Pancreatic Adenocarcinoma
干预: mFOLFIRINOX or Gemcitabine nab-paclitaxel，Isotoxic High-Dose (iHD)-SBRT，Surgery
地点: Belgium
申办方: Erasme University Hospital

正在招募 Phase 2 联合产品放疗

clinicaltrials.gov NCT04570943

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: Gabrinox，MRI-GUIDED STEREOTACTIC RADIOTHERAPY
地点: France
申办方: Institut du Cancer de Montpellier - Val d'Aurelle

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05000294

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

适用疾病: Bile Duct Cancer；Gall Bladder Cancer；Breast Cancer
干预: Atezolizumab，Tivozanib
地点: United States
申办方: University of Florida

即将招募 Phase 1 药物

clinicaltrials.gov NCT07583771

A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma

适用疾病: Pancreatic Adenocarcinoma；Non Small Cell Lung Cancer；Advanced Solid Tumors
干预: CS08399
地点: China
申办方: Chipscreen Biosciences, Ltd.

正在招募 Phase 3 药物

clinicaltrials.gov NCT07252232

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

适用疾病: Pancreatic Cancer；PDAC；PDAC - Pancreatic Ductal Adenocarcinoma
干预: daraxonrasib
地点: United States，France，Italy，Japan 等 3 个
申办方: Revolution Medicines, Inc.

即将招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07670312

Evaluation of XYA02 in Patients With Advanced Solid Tumors

适用疾病: MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors；Non-Small Cell Lung Cancer；Ovarian Cancer
干预: XYA02
地点: Australia
申办方: XYone Therapeutics, Inc

正在招募 Phase 1 生物制剂药物其他

clinicaltrials.gov NCT04119024

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

适用疾病: Metastatic Malignant Solid Neoplasm；Metastatic Melanoma；Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
干预: Biopsy，Biospecimen Collection，Computed Tomography，Cyclophosphamide
地点: United States
申办方: Anusha Kalbasi

正在招募 Phase 1 器械药物

clinicaltrials.gov NCT04150042

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

适用疾病: Pancreatic Adenocarcinoma Metastatic；BRCA1 Mutation；BRCA2 Mutation
干预: Melphalan，BCNU，Vitamin B12B，Vitamin C
地点: United States
申办方: General Oncology, Inc.

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06843551

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma；Metastatic Pancreatic Cancer
干预: Stereotactic Body Radiation Therapy，Botensilimab，Balstilimab
地点: United States
申办方: Benjamin Spieler

即将招募 Phase 3 药物放疗

clinicaltrials.gov NCT07336953

A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)

适用疾病: PDAC - Pancreatic Ductal Adenocarcinoma
干预: GnP，SBRT，Serplulimab
地点: 未列出
申办方: West China Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT06562192

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

适用疾病: Pancreatic Ductal Adenocarcinoma；Non-small Cell Lung Cancer；HR+/HER2- Ductal and Lobular Breast Cancer
干预: [68Ga]Ga-NNS309，[177Lu]Lu-NNS309
地点: United States，Belgium，Canada，France 等 6 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT07306273

IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

适用疾病: Pancreatic Adenocarcinoma Locally Advanced
干预: Irreversible electroporation，Dual-Function Antibody PD-1/CTLA-4
地点: China
申办方: Ruijin Hospital

正在招募阶段未标明药物

clinicaltrials.gov NCT07408505

Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer

适用疾病: Advanced Pancreatic Ductal Adenocarcinoma；Cancer Anorexia-Cachexia Syndrome
干预: Nano-crystalline megestrol acetate，First-line Chemotherapy
地点: China
申办方: Shandong Cancer Hospital and Institute

正在招募 Phase 2 药物

clinicaltrials.gov NCT07644559

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；G12D Mutated KRAS
干预: VS-7375，cetuximab
地点: United States，Australia
申办方: Verastem, Inc.

即将招募 Phase 1 药物

clinicaltrials.gov NCT07566897

A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

适用疾病: Renal Carcinoma Metastatic；Pancreatic Adenocarcinoma Metastatic；Pancreatic Adenocarcinoma
干预: L19IL2，Ruxolitinib
地点: Italy
申办方: Philogen S.p.A.

正在招募 Phase 1 药物

clinicaltrials.gov NCT05759923

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

适用疾病: Advanced Ovarian Carcinoma；Advanced Renal Cell Carcinoma；Advanced Pancreatic Carcinoma
干预: OATD-02
地点: Poland
申办方: Molecure S.A.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07240766

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

适用疾病: Borderline Resectable Pancreatic Adenocarcinoma
干预: HRS-4642+AG+Nimotuzumab
地点: China
申办方: Zhejiang University

正在招募 Phase 1 药物

clinicaltrials.gov NCT07021066

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

适用疾病: Gastric Adenocarcinoma；Advanced Pancreatic Ductal Adenocarcinoma；Esophageal Adenocarcinoma
干预: BL-M05D1
地点: United States
申办方: SystImmune Inc.

正在招募阶段未标明其他手术/操作

clinicaltrials.gov NCT05132244

Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

适用疾病: Pancreatic Cancer；PDAC - Pancreatic Ductal Adenocarcinoma；Hyperglycemia
干预: Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)，Standard Care
地点: Canada
申办方: British Columbia Cancer Agency

正在招募 Phase 3 药物

clinicaltrials.gov NCT07562152

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

适用疾病: Pancreatic Cancer；Pancreatic Cancer Metastatic；PDAC
干预: Atebimetinib，GnP，mGnP
地点: United States，Australia
申办方: Immuneering Corporation

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07488676

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

适用疾病: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma；Pancreatic Adenocarcinoma
干预: ASP546C
地点: United States，Japan
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06673017

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

适用疾病: Pancreatic Ductal Adenocarcinoma；Borderline Resectable Pancreatic Adenocarcinoma；Locally Advanced Pancreatic Adenocarcinoma
干预: PTM-101
地点: United States
申办方: PanTher Therapeutics

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07678593

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

适用疾病: Advanced Solid Tumors Cancer；Pancreatic Ductal Adenocarcinoma；RAS Mutation
干预: GFH276，Cetuximab，Nab paclitaxel，Gemcitabine
地点: Australia，China
申办方: Genfleet Therapeutics (Shanghai) Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07189195

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

适用疾病: Advanced Malignant Solid Neoplasm；Metastatic Malignant Solid Neoplasm；Metastatic Pancreatic Adenocarcinoma
干预: TR-002
地点: United States
申办方: University of California, Davis

正在招募 Phase 3 药物

clinicaltrials.gov NCT07165951

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma
干预: TQB2868 Injection，Anlotinib Hydrochloride Capsules，Gemcitabine Hydrochloride Injection，Paclitaxel for Injection
地点: China
申办方: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07030283

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)
干预: Paclitaxel，NALIRIFOX
地点: United States
申办方: University of Colorado, Denver

即将招募 Phase 1 生物制剂药物手术/操作

clinicaltrials.gov NCT07619313

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

适用疾病: Borderline Resectable Pancreatic Ductal Adenocarcinoma；Locally Advanced Cholangiocarcinoma；Locally Advanced Pancreatic Adenocarcinoma
干预: Biopsy Procedure，Cisplatin，Computed Tomography，Durvalumab
地点: United States
申办方: Jonsson Comprehensive Cancer Center

正在招募 Phase 1 联合产品

clinicaltrials.gov NCT06639724

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)
干预: Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
地点: United States
申办方: University of California, San Diego

正在招募 Phase 2 药物

clinicaltrials.gov NCT05821556

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

适用疾病: Adenocarcinoma of the Pancreas
干预: Valproic acid，Simvastatin 20mg，Gemcitabine 1000 mg，Nab paclitaxel
地点: Italy，Spain
申办方: National Cancer Institute, Naples

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06427239

Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

适用疾病: Pancreatic Cancer
干预: HRS-4642，Adebrelimab，SHR-8068，Faminitib or bevacizumab
地点: China
申办方: Fudan University

正在招募 Phase 1, Phase 2 联合产品

clinicaltrials.gov NCT07284277

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

适用疾病: Pancreatic Adenocarcinoma Metastatic；Pancreatic Ductal Adenocarcinoma
干预: TTFields concomitant with modFOLFIRINOX
地点: Spain
申办方: Clinica Universidad de Navarra, Universidad de Navarra

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07172802

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Non-small Cell Lung Cancer (NSCLC)
干预: GI-108
地点: South Korea
申办方: GI Innovation, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06790602

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

适用疾病: Pancreatic Ductal Adenocarcinoma (mPDAC)
干预: Cemiplimab Plus Gemcitabine
地点: United States
申办方: University of California, San Diego

正在招募 Phase 2 药物

clinicaltrials.gov NCT06757244

DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer

适用疾病: Pancreas Neoplasms
干预: Dostarlimab，Vitamin D3 (Cholecalciferol)，mFOLFIRINOX Treatment Regimen，LV5FU2
地点: France
申办方: Hopital Foch

即将招募 Phase 2 药物

clinicaltrials.gov NCT07415525

IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer

适用疾病: Pancreatic Cancer；Borderline Resectable Pancreatic Adenocarcinoma
干预: IBI343
地点: China
申办方: Zhejiang University

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT06428409

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

适用疾病: Colorectal Cancer；Pancreatic Ductal Adenocarcinoma；Biliary Tract Cancer
干预: Sacituzumab tirumotecan，Fluorouracil (5-FU)，Leucovorin (LV) or levoleucovorin，Rescue medication
地点: United States，Australia，Canada，Chile 等 9 个
申办方: Merck Sharp & Dohme LLC

即将招募 Phase 1 药物

clinicaltrials.gov NCT07624214

Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: LT-010391
地点: China
申办方: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07549958

PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)

适用疾病: Pancreatic Cancer；Pancreatic Cancer Metastatic
干预: Pitavastatin
地点: United States
申办方: University of California, Irvine

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06048484

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Stereotactic body radiotherapy (SBRT)，Zimberelimab，Quemliclustat，Etrumadenant
地点: United States
申办方: Gulam Manji

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT05733000

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

适用疾病: Advanced Biliary Tract Carcinoma；Advanced Colorectal Carcinoma；Advanced Gastroesophageal Junction Adenocarcinoma
干预: Biospecimen Collection，Computed Tomography，Devimistat，Fluorouracil
地点: United States
申办方: Northwestern University

正在招募 Phase 1 药物

clinicaltrials.gov NCT06393400

CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)

适用疾病: Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma
干预: Fecal Microbiota Transplantation，PEG3350，Gemcitabine，nab-Paclitaxel
地点: Canada
申办方: John Lenehan

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07610798

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

适用疾病: Advance Solid Tumors；Colon and Rectal Cancer；Non - Small Cell Lung Cancer NSCLC
干预: INV-8989
地点: China
申办方: Shenzhen Ionova Life Sciences Co., Ltd.

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT07022015

Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy

适用疾病: Pancreas Cancer；Pancreas Neoplasm；Pancreatic Fistula
干预: pancreaticoduodenectomy procedure
地点: Egypt
申办方: Minia University

正在招募 Phase 1, Phase 2 药物放疗

clinicaltrials.gov NCT06384560

Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

适用疾病: Localized Pancreatic Adenocarcinoma；Borderline Resectable Pancreatic Adenocarcinoma；Resectable Pancreatic Adenocarcinoma
干预: Pembrolizumab，Folfirinox，SABR
地点: Netherlands
申办方: Amsterdam UMC, location VUmc

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT07656571

Indocyanine Green-Guided Versus Standard Laparoscopic Distal Pancreatectomy for Pancreatic Body and Tail Lesions

适用疾病: Pancreatic Neoplasms；Pancreatic Cancer
干预: ICG Fluorescence-Guided Laparoscopic Distal Pancreatectomy，Standard Laparoscopic Distal Pancreatectomy
地点: Egypt
申办方: Alexandria University

正在招募 Phase 1 药物

clinicaltrials.gov NCT05365581

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

适用疾病: Gastric Adenocarcinoma；Gastroesophageal Junction (GEJ) Adenocarcinoma；Pancreatic Adenocarcinoma
干预: ASP2138，Pembrolizumab，Oxaliplatin，Leucovorin
地点: United States，China，France，Italy 等 4 个
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07483983

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

适用疾病: Metastatic/Locally Advanced Non-Small-Cell Lung Cancer；Metastatic/Locally Pancreatic Ductal Adenocarcinoma
干预: ASP3082
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT04146298

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

适用疾病: Pancreatic Cancer；Pancreatic Neoplasms；Pancreatic Ductal Adenocarcinoma
干预: Cyclophosphamide，Fludarabine，Mutant KRAS G12V-specific TCR transduced autologous T cells，Anti-PD-1 monoclonal antibody
地点: China
申办方: Changhai Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT07621718

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

适用疾病: Pancreatic Cancer；Pancreatic Cancer Metastatic；PDAC
干预: Zoldonrasib，Placebo，Oxaliplatin，Leucovorin (Calcium Folinate)
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06648434

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma；Pancreatic Cancer；Cancer of the Pancreas
干预: Zunsemetinib，mFOLFIRINOX
地点: United States
申办方: Washington University School of Medicine

正在招募阶段未标明其他手术/操作

clinicaltrials.gov NCT07493421

To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.

适用疾病: Pancreatic Adenocarcinoma；Peritoneal (Metastatic) Cancer
干预: Pancreatectomy，Complete Cytoreduction，Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
地点: China，Portugal
申办方: Unidade Local de Saúde São João

正在招募 Phase 2 药物其他

clinicaltrials.gov NCT05825066

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

适用疾病: Pancreas Adenocarcinoma；Borderline Resectable Pancreatic Adenocarcinoma；Locally Advanced Pancreatic Adenocarcinoma
干预: Nab paclitaxel，Gemcitabine，Radiological Assessments，mFOLFIRINOX
地点: United States
申办方: Wake Forest University Health Sciences

即将招募 Phase 1 药物

clinicaltrials.gov NCT07637786

Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer

适用疾病: Advanced Pancreatic Adenocarcinoma
干预: ONVAX-01 plus Anti-PD-1 and Chemotherapy
地点: China
申办方: Sichuan University

正在招募 Phase 1 联合产品

clinicaltrials.gov NCT06229496

Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma

适用疾病: Metastatic Pancreatic Adenocarcinoma
干预: Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA)，Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)，Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)
地点: Taiwan
申办方: Chang Gung Memorial Hospital

正在招募 Phase 1 药物手术/操作

clinicaltrials.gov NCT06454383

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

适用疾病: Advanced Pancreatic Adenocarcinoma；Stage III Pancreatic Cancer AJCC v8；Stage IV Pancreatic Cancer AJCC v8
干预: Biospecimen Collection，Cholestyramine，Computed Tomography，Diagnostic Imaging
地点: United States
申办方: City of Hope Medical Center

正在招募阶段未标明药物放疗

clinicaltrials.gov NCT06691425

Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma

适用疾病: Non-metastasized Unresectable Pancreatic Carcinoma
干预: Stereotactic Body Radiation Therapy (SBRT)，Chemotherapy
地点: Belgium
申办方: Cancer Research Antwerp

正在招募 Phase 1 器械药物

clinicaltrials.gov NCT07253662

Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

适用疾病: Adenocarcinoma Pancreas
干预: PIPAC，Nab-paclitaxel
地点: United States
申办方: Northwell Health

即将招募 Phase 2 联合产品放疗

clinicaltrials.gov NCT07097064

Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: standard radiotherapy with chemotherapy，MRI-guided adaptive stereotactic radiotherapy (SMART)
地点: France
申办方: Institut du Cancer de Montpellier - Val d'Aurelle

正在招募 Phase 2 药物

clinicaltrials.gov NCT06333314

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

适用疾病: Pancreatic Adenocarcinoma；Ampulla of Vater Carcinoma；Adrenocortical Carcinoma
干预: Dostarlimab，Chemotherapy
地点: France
申办方: UNICANCER

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05288205

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

适用疾病: KRAS P.G12C；Non-small Cell Lung Cancer；Colorectal Cancer
干预: JAB-21822，JAB-3312
地点: China
申办方: Allist Pharmaceuticals, Inc.

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT04571294

Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy

适用疾病: Pancreas Cancer；Pancreaticoduodenal Lymphadenopathy；Pancreas Adenocarcinoma
干预: removal of para-aortic lymphnodes (PALN)
地点: Italy
申办方: Humanitas Hospital, Italy

正在招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT07595237

A IIT Study of 177Lu-DOTA-SNA040

适用疾病: Advanced Solid Tumors (Such as Gastric Cancer)；Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)；Advanced Solid Tumors (Such as Pancreatic Cancer)
干预: 177Lu-DOTA-SNA040
地点: China
申办方: SmartNuclide Biopharma

正在招募 Phase 1, Phase 2 药物手术/操作

clinicaltrials.gov NCT04851119

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

适用疾病: Colorectal Carcinoma；Endometrial Carcinoma；Melanoma
干预: Biospecimen Collection，Dual X-ray Absorptiometry，Tegavivint，X-Ray Imaging
地点: United States
申办方: Children's Oncology Group

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT07148830

Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.

适用疾病: Pancreatic Ductal Adenocarcinoma；Pancreatic Cancer
干预: Total Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy)
地点: Egypt
申办方: Minia University

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT04858334

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

适用疾病: Pancreatic Acinar Cell Carcinoma；Pancreatic Adenosquamous Carcinoma；Pancreatic Squamous Cell Carcinoma
干预: Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging，Olaparib
地点: United States，Israel，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

clinicaltrials.gov NCT07255404

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)
干预: Pumitamig，Nab-paclitaxel，Gemcitabine，mFOLFIRINOX
地点: China
申办方: BioNTech SE

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05431270

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

适用疾病: Non Small Cell Lung Cancer；Pancreatic Ductal Adenocarcinoma
干预: Mavrostobart (PT199)，Tislelizumab，Gemcitabine + nab-Paclitaxel，Docetaxel
地点: United States
申办方: Phanes Therapeutics

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06861452

Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: RR001
地点: Italy
申办方: EIR Biotherapies s.r.l.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06586515

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

适用疾病: Pancreatic Ductal Adenocarcinoma；Non-small Cell Lung Cancer；Colorectal Cancer
干预: LY3962673，Cetuximab，Gemcitabine，nab-paclitaxel
地点: United States，Canada，China，France 等 5 个
申办方: Eli Lilly and Company

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06922591

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

适用疾病: PDAC；PDAC - Pancreatic Ductal Adenocarcinoma；NSCLC
干预: TNG462，RMC-9805，RMC-6236，mFOLFIRINOX
地点: United States
申办方: Tango Therapeutics, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07024615

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: ASP2138，Oxaliplatin，Leucovorin，5-FU
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1 联合产品

clinicaltrials.gov NCT07481383

A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer

适用疾病: Pancreatic Adenocarcinoma Non-resectable
干预: ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003)
地点: United States
申办方: Continuity Biosciences, LLC

正在招募 Phase 1 药物

clinicaltrials.gov NCT06596915

Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

适用疾病: Non-Small Cell Lung Cancer；Pancreatic Adenocarcinoma；Breast Cancer
干预: BA1302
地点: China
申办方: Shandong Boan Biotechnology Co., Ltd

即将招募阶段未标明药物手术/操作

clinicaltrials.gov NCT05611359

Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Thermal Ablation，Chemotherapy
地点: 未列出
申办方: Second Affiliated Hospital, School of Medicine, Zhejiang University

即将招募阶段未标明手术/操作

clinicaltrials.gov NCT04253847

RAMPS VS SRPS for Pancreatic Body and Tail Adenocarcinoma

适用疾病: Radical Antegrade Modular Pancreatosplenectomy
干预: Radical antegrade modular pancreatosplenectomy，Standard retrograde pancreatosplenectomy
地点: China
申办方: Ruijin Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07529808

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

适用疾病: Gastric Cancer；Gastric Adenocarcinoma；Gastric (Stomach) Cancer
干预: BHB810
地点: United States
申办方: BigHat Biosciences, Inc.

即将招募阶段未标明药物

clinicaltrials.gov NCT07014254

Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Adenocarcinoma of the Stomach；Colorectal Cancer Metastatic
干预: 177Lu-CTR-FAPI nuclide-targeted therapy
地点: China
申办方: Xijing Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT03977233

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Cancer of Pancreas；Pancreatic Cancer, Adult
干预: Oxaliplatin，Leucovorin，Irinotecan Hydrochloride，5-FU
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1 药物

clinicaltrials.gov NCT07094204

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

适用疾病: Solid Tumor；Non-Small-Cell Lung Cancer；Pancreatic Ductal Adenocarcinoma
干预: ASP5834，panitumumab
地点: United States，France，Japan，Spain
申办方: Astellas Pharma Inc

正在招募 Phase 1 药物

clinicaltrials.gov NCT06458712

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

适用疾病: Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Metastases)
干预: DSB2455
地点: United States，France，Hungary，Spain
申办方: Duke Street Bio Ltd

即将招募 Phase 1 药物手术/操作

clinicaltrials.gov NCT07645651

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

适用疾病: Resectable Pancreatic Ductal Adenocarcinoma；Borderline Resectable Pancreatic Ductal Adenocarcinoma；Locally Advanced Pancreatic Ductal Adenocarcinoma
干预: Samuraciclib，Computed Tomography，Endoscopic Ultrasound Biopsy，Biospecimen Collection
地点: United States
申办方: University of Washington

正在招募 Phase 1 药物

clinicaltrials.gov NCT07165132

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

适用疾病: GEP-NET；Gastroenteropancreatic Neuroendocrine Tumor；Gastroenteropancreatic Neuroendocrine Tumor Disease
干预: RYZ401
地点: United States，Canada
申办方: RayzeBio, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06999187

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

适用疾病: Triple Negative Breast Cancer；HER2-negative Breast Cancer；Non Small Cell Lung Cancer
干预: DR-0202
地点: United States
申办方: Dren Bio

正在招募 Phase 2 联合产品药物

clinicaltrials.gov NCT06850623

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: Acoustic Cluster Therapy，Modified FOLFIRINOX
地点: United States，United Kingdom
申办方: EXACT Therapeutics AS

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07665684

Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer

适用疾病: Pancreas Ductal Adenocarcinoma；Pancreas Cancer, Metastatic；Pancreatic Adenocarcinoma Metastatic
干预: Samuraciclib + Gemcitabine & Nab-Paclitaxel
地点: Canada
申办方: University Health Network, Toronto

即将招募 Phase 1 药物

clinicaltrials.gov NCT06217666

Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)

适用疾病: Pancreatic Adenocarcinoma
干预: PCX-12
地点: United States
申办方: Haoming (Carl) Qiu

正在招募 Phase 3 药物手术/操作

clinicaltrials.gov NCT07155525

Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas

适用疾病: Pancreatic Cancer；Periampullary Cancer；Duodenal Cancer
干预: Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2)，Standard(duct-to-mucosa) Pancreaticojejunostomy
地点: Egypt
申办方: Minia University

即将招募 Phase 3 药物

clinicaltrials.gov NCT05314998

Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Oxaliplatin，Irinotecan，Folinic acid，5-fluorouracil
地点: Germany，Sweden
申办方: John Neoptolemos

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06508307

A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors

适用疾病: Sarcoma；Cervical Cancer；Colon Cancer
干预: A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors
地点: China
申办方: GONGCHU Biotechnology Co., Ltd

正在招募 Phase 1, Phase 2 药物其他手术/操作

clinicaltrials.gov NCT04172532

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

适用疾病: Locally Advanced Pancreatic Adenocarcinoma；Stage III Pancreatic Cancer AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Hypofractionated Radiation Therapy
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07235202

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)
干预: MR001，Irinotecan Liposome Injection combined with 5-FU/LV，Nab-paclitaxel，Gemcitabine (GEM)
地点: China
申办方: Shenzhen Majory Biotechnology Co., Ltd.

正在招募 EARLY / Phase 1 生物制剂

clinicaltrials.gov NCT06828328

A Study of GC203 TIL in PDCA (RJ)

适用疾病: Pancreatic Cancer；Pancratic Ductal Adenocarcinoma；Treatment Side Effects
干预: GC203 TIL
地点: China
申办方: Shanghai Juncell Therapeutics

正在招募 Phase 2 药物

clinicaltrials.gov NCT06199895

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

适用疾病: Pancreatic Adenocarcinoma；Cholangiocarcinoma；Lung Cancer
干预: Paclitaxel Polymeric Micelles for Injection
地点: China
申办方: Liu Huang

即将招募 Phase 1 药物

clinicaltrials.gov NCT06981806

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma
干预: Balixafortide，Balixafortide，Cosibelimab，Balixafortide
地点: United States
申办方: Arsen Osipov

正在招募 Phase 2 药物

clinicaltrials.gov NCT05132504

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Pembrolizumab，Folfirinox
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 2 药物

clinicaltrials.gov NCT03175224

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

适用疾病: Solid Tumors；Advanced Cancer；Renal Cancer
干预: APL-101 Oral Capsules
地点: United States，Australia，Canada，France 等 7 个
申办方: Apollomics Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07450859

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)
干预: nuzefatide pevedotin (BT5528)
地点: United States
申办方: BicycleTx Limited

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT06079346

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: OT-101，mFOLFIRINOX
地点: United States
申办方: Oncotelic Inc.

正在招募阶段未标明放疗

clinicaltrials.gov NCT03704662

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

适用疾病: Pancreatic Cancer
干预: Stereotactic Body Radiation Therapy，Preoperative Fractionated Radiation Therapy and Chemotherapy
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 3 药物

clinicaltrials.gov NCT04969731

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Immuncell-LC，Gemcitabine
地点: South Korea
申办方: GC Cell Corporation

正在招募 Phase 3 药物

clinicaltrials.gov NCT07409272

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

适用疾病: Pancreatic Cancer；Metastatic Pancreatic Cancer；Metastatic Pancreatic Adenocarcinoma
干预: Setidegrasib，Oxaliplatin，Leucovorin，Irinotecan
地点: United States，Japan
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT07480928

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Unresectable Locally Advanced or Metastatic Disease
干预: EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)，EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)，Lymphodepleting chemotherapy (Flu/Cy)
地点: China
申办方: Beijing Biotech

即将招募 Phase 2 药物

clinicaltrials.gov NCT07565155

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

适用疾病: Pancreatic Adenocarcinoma；Homologous Recombination Deficiency
干预: Lorigerlimab
地点: United States
申办方: Peter Hosein, MD

正在招募 Phase 2 药物

clinicaltrials.gov NCT06261359

A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)
干预: CEND-1，Gemcitabine，Nab paclitaxel
地点: China
申办方: Qilu Pharmaceutical Co., Ltd.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07106827

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

适用疾病: HCC - Hepatocellular Carcinoma；Cholangiocarcinoma；Melanoma
干预: GV20-0251
地点: China
申办方: West China Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT04999761

AB122 Platform Study

适用疾病: Advanced or Metastatic Solid Tumor；Pancreatic Ductal Adenocarcinoma；Colorectal Cancer
干预: AB122，AB122，TAS-116，AB122
地点: Japan
申办方: Taiho Pharmaceutical Co., Ltd.

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07435038

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: BPI-572270
地点: 未列出
申办方: Betta Pharmaceuticals Co., Ltd.

正在招募 Phase 2 联合产品

clinicaltrials.gov NCT06149689

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer

适用疾病: Pancreatic Adenocarcinoma
干预: mFOLFIRINOX plus radiotherapy
地点: China
申办方: Fudan University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05379985

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: RMC-6236
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 2 联合产品药物

clinicaltrials.gov NCT05851924

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: NALIRIFOX，AD-XRT and Capecitabine
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 药物

clinicaltrials.gov NCT07454642

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

适用疾病: Vulvar Adenocarcinoma；PDAC - Pancreatic Ductal Adenocarcinoma；Gastric Adenocarcinoma
干预: AVA6103
地点: United States
申办方: Avacta Life Sciences Ltd

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07685470

MRG003 With Gemcitabine for Second-line Advanced PDAC

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Second Line Treatment
干预: becotatugvedotin plus gemcitabine
地点: 未列出
申办方: Peking Union Medical College Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06387342

Namodenoson Treatment of Advanced Pancreatic Cancer

适用疾病: Pancreatic Adenocarcinoma；Pancreatic Cancer
干预: Namodenoson 25mg
地点: Israel
申办方: Can-Fite BioPharma

正在招募 Phase 1, Phase 2 药物放疗

clinicaltrials.gov NCT04789486

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

适用疾病: Non-small Cell Lung Cancer；Advanced Pancreatic Adenocarcinoma；Unresectable Pancreatic Cancer
干预: AGuIX，Radiotherapy
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07157033

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

适用疾病: Locally Advanced Pancreatic Adenocarcinoma；Locally Advanced Pancreas Cancer；Locally Advanced Pancreatic Ductal Adenocarcinoma
干预: XER-001
地点: United States
申办方: Xerient Pharma

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT06095141

Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency

适用疾病: Pancreatic Adenocarcinoma；Homologous Recombination Deficiency
干预: Cisplatin
地点: China
申办方: Fudan University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07049055

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

适用疾病: Pancreatic Cancer, Metastatic；PDAC - Pancreatic Ductal Adenocarcinoma
干预: E-EDV-D682，EDV-GC，Gemcitabine，Nab paclitaxel.
地点: United States
申办方: Engeneic Pty Limited

正在招募 Phase 1 药物

clinicaltrials.gov NCT07481357

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

适用疾病: Gastric (Stomach) Cancer；GastroEsophageal Cancer；Pancreatic Ductal Adenocarcinoma (mPDAC)
干预: DA-3501
地点: South Korea
申办方: Dong-A ST Co., Ltd.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06060405

Durvalumab and Oleclumab in Resectable PDAC

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Durvalumab，Oleclumab
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1 药物

clinicaltrials.gov NCT06131840

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

适用疾病: Colorectal Neoplasms；Carcinoma, Non-Small-Cell Lung；Stomach Neoplasms
干预: PF-08046050，bevacizumab，5-Fluorouracil (5-FU)，Oxaliplatin
地点: United States，Canada，China，France 等 5 个
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06445062

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

适用疾病: Colorectal Cancer；CRC；Pancreatic Ductal Adenocarcinoma
干预: RMC-6236，mFOLFOX6 regimen，bevacizumab，mFOLFIRINOX regimen
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT07490301

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma；PDAC
干预: Telisotuzumab adizutecan，Fluorouracil，Folinic acid/ Leucovorina，Oxaliplatin
地点: United States，Australia，Israel，Japan 等 3 个
申办方: AbbVie

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06218914

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

适用疾病: Non-small Cell Lung Cancer；Colorectal Carcinoma；Pancreatic Ductal Adenocarcinoma
干预: NT-112: Autologous, engineered T Cells targeting KRAS G12D，AZD0240: Autologous, engineered T Cells targeting KRAS G12D
地点: United States
申办方: AstraZeneca

正在招募 Phase 3 药物

clinicaltrials.gov NCT05482516

Evaluating Novel Therapies in ctDNA Positive GI Cancers

适用疾病: Colon Adenocarcinoma；Rectal Adenocarcinoma；Gastric Adenocarcinoma
干预: Atezolizumab，Bevacizumab
地点: United States
申办方: Georgetown University

正在招募 Phase 2 放疗

clinicaltrials.gov NCT07269626

PULSAR in Systemic Therapy for Pancreatic Cancer

适用疾病: Locally Advanced Pancreatic Ductal Adenocarcinoma；Borderline Resectable Pancreatic Ductal Adenocarcinoma；Oligometastatic Pancreatic Ductal Adenocarcinoma
干预: Personalized Ultrafractionated Adaptive Radiotherapy
地点: South Korea
申办方: Samsung Medical Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT05968326

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

适用疾病: Adenocarcinoma, Pancreatic Ductal
干预: Autogene cevumeran，Atezolizumab，mFOLFIRINOX
地点: United States，Belgium，Canada，France 等 6 个
申办方: Genentech, Inc.

即将招募 Phase 2 药物

clinicaltrials.gov NCT06361030

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

适用疾病: Pancreatic Cancer；Pancreatic Cancer Non-resectable；Pancreatic Ductal Adenocarcinoma, PDAC
干预: surufatinib combined with gemcitabine plus nab-paclitaxel
地点: China
申办方: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

正在招募 Phase 1 药物

clinicaltrials.gov NCT04389632

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

适用疾病: Carcinoma, Non-Small Cell Lung；Squamous Cell Carcinoma of Head and Neck；HER2 Negative Breast Neoplasms
干预: sigvotatug vedotin，pembrolizumab，cisplatin，carboplatin
地点: United States，France，South Korea，Spain 等 3 个
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06598007

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

适用疾病: Solid Tumor, Adult；Colorectal Cancer；Pancreatic Ductal Adenocarcinoma
干预: CT3001，FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
地点: United States
申办方: Crossignal Therapeutics, Inc.

即将招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT06156267

Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino

适用疾病: Pancreatic Cancer
干预: Adebrelimab，mRNA tumor vaccines
地点: China
申办方: Fudan University

正在招募 Phase 2 药物

clinicaltrials.gov NCT04926467

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

适用疾病: Pancreatic Adenocarcinoma
干预: Anakinra
地点: United States
申办方: Baylor Research Institute

正在招募阶段未标明诊断检测药物

clinicaltrials.gov NCT06966440

Adjuvant Pancreatic Therapy Guided by MRD

适用疾病: Pancreatic Adenocarcinoma Resectable
干预: circulating tumor DNA (ctDNA)-based MRD，adjuvant chemotherapy regimens
地点: China
申办方: Ruijin Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT06714604

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

适用疾病: Locally Advanced Pancreatic Adenocarcinoma；Borderline Resectable Pancreatic Carcinoma；Pancreas Cancer
干预: FOLFIRINOX or gemcitabine-nab-paclitaxel，FOLFIRINOX or gemcitabine-nab-paclitaxel
地点: Sweden
申办方: Sahlgrenska University Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT07199764

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Odetiglucan，Mitazalimab
地点: United States
申办方: University of Pennsylvania

正在招募阶段未标明放疗

clinicaltrials.gov NCT06984562

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

适用疾病: Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
干预: Adaptive Radiation Therapy
地点: United States
申办方: Fox Chase Cancer Center

正在招募 Phase 1 药物

clinicaltrials.gov NCT06835569

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

适用疾病: Cancer；PDAC - Pancreatic Ductal Adenocarcinoma；NSCLC (Non-small Cell Lung Cancer)
干预: ALTA3263，cetuximab，mFOLFOX6，Pembrolizumab
地点: United States
申办方: Alterome Therapeutics, Inc.

即将招募 Phase 2 药物

clinicaltrials.gov NCT06750861

QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC

适用疾病: Pancreatic Adenocarcinoma
干预: QL1706
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

即将招募 Phase 2 药物

clinicaltrials.gov NCT07616362

Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.

适用疾病: Borderline Resectable Pancreatic Ductal Adenocarcinoma
干预: Nab paclitaxel / gemcitabine，mFOLFIRINOX
地点: France
申办方: Federation Francophone de Cancerologie Digestive

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

适用疾病: Head and Neck Carcinoma；Adenoid Cystic Carcinoma；Lung Cancer
干预: VMD-928 100 mg Tablet，VMD-928 Tablet and Pembrolizumab (200 mg)
地点: United States，Puerto Rico
申办方: VM Oncology, LLC

正在招募 Phase 1, Phase 2 生物制剂诊断检测

clinicaltrials.gov NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

适用疾病: Solid Tumor, Adult；Colorectal Cancer；NSCLC
干预: A2B694，A2B543，xT CDx with HLA-LOH Assay
地点: United States
申办方: A2 Biotherapeutics Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT04900818

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

适用疾病: Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: TJ033721 (givastomig)，TJ033721 (givastomig) , nivolumab, chemotherapy，TJ033721 (givastomig), chemotherapy，TJ033721 (givastomig), durvalumab, chemotherapy
地点: United States，China
申办方: I-Mab Biopharma US Limited

即将招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07153289

CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)

适用疾病: Carcinoma, Pancreatic Ductal；Pancreatic Neoplasms
干预: CD318-CAR-T cells
地点: 未列出
申办方: University Hospital Tuebingen

正在招募 Phase 1 药物

clinicaltrials.gov NCT07261631

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

适用疾病: Pancreatic Ductal Adenocarcinoma；Non-Small Cell Lung Cancer；HR+/HER2- Ductal and Lobular Breast Cancer
干预: 68Ga-NNS309，177Lu-DFC413
地点: Canada，Denmark，France，Germany 等 2 个
申办方: Novartis Pharmaceuticals

即将招募 Phase 2 药物

clinicaltrials.gov NCT07108504

Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer；Chemotherapy Effect
干预: Gemcitabine，LM-302
地点: 未列出
申办方: Shanghai Zhongshan Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06483555

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

适用疾病: Pancreatic Adenocarcinoma；Metastatic Pancreatic Cancer；Basal Cell Neoplasm
干预: Gemcitabine，Nab paclitaxel，Erlotinib，NALIRIFOX
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1, Phase 2 放疗

clinicaltrials.gov NCT06024824

Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)

适用疾病: Pancreatic Adenocarcinoma
干预: Dose-Painted Intensity Modulated Radiotherapy
地点: Ireland
申办方: Cancer Trials Ireland

正在招募 Phase 3 药物手术/操作

clinicaltrials.gov NCT07081360

Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer

适用疾病: Pancreas Cancer；Periampullary Cancer；Periampullary Carcinoma Resectable
干预: Neoadjuvant chemotherapy，Upfront Surgery Group
地点: Egypt
申办方: Minia University

正在招募 Phase 1 药物

clinicaltrials.gov NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

适用疾病: Mesothelioma；Non Small Cell Lung Cancer；Malignant Peripheral Nerve Sheath Tumors
干预: MRTX1719
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT04895709

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

适用疾病: Cervical Cancer；Gastric/Gastroesophageal Junction Adenocarcinoma；Microsatellite Stable Colorectal Cancer
干预: BMS-986340，BMS-936558-01，Docetaxel，Pumitamig
地点: United States，Australia，Canada，Germany 等 4 个
申办方: Bristol-Myers Squibb

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT03492671

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

适用疾病: Pancreas Adenocarcinoma；Resectable Pancreatic Cancer
干预: Gemcitabine 1000 mg，nab-paclitaxel，Stereotactic Body Radiation Therapy
地点: United States
申办方: Loma Linda University

正在招募 Phase 2 器械药物

clinicaltrials.gov NCT05624918

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

适用疾病: Pancreatic Adenocarcinoma；Resectable Pancreatic Cancer
干预: Nab paclitaxel，Gemcitabine，NovoTTF-200T(P)
地点: United States
申办方: Ashish Manne

正在招募 EARLY / Phase 1 生物制剂药物

clinicaltrials.gov NCT04005690

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

适用疾病: Locally Advanced Pancreatic Ductal Adenocarcinoma；Metastatic Pancreatic Ductal Adenocarcinoma；Stage II Pancreatic Cancer AJCC v8
干预: Cobimetinib，Olaparib，Onvansertib，Azenosertib
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 2 药物

clinicaltrials.gov NCT07259317

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

适用疾病: Adenocarcinoma；Carcinoma, Pancreatic Ductal
干预: Relacorilant，Nab-paclitaxel，Gemcitabine
地点: United States
申办方: Corcept Therapeutics

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06792435

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

适用疾病: Pancreatic Adenocarcinoma Metastatic；Lung Cancer (NSCLC)；Ovarian Cancer
干预: XNW27011，XNW27011
地点: China
申办方: Evopoint Biosciences Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

适用疾病: NSCLC Adenocarcinoma；Gastroesophageal Cancer (GC)；Gastric Adenocarcinoma
干预: IDE892，IDE397
地点: United States
申办方: IDEAYA Biosciences

正在招募 EARLY / Phase 1 药物手术/操作

clinicaltrials.gov NCT07089940

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

适用疾病: Locally Advanced Pancreatic Ductal Adenocarcinoma；Metastatic Pancreatic Ductal Adenocarcinoma；Stage II Pancreatic Cancer AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05257993

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: JPI-547，modified FOLFIRINOX，Gemcitabine-nab-paclitaxel
地点: South Korea
申办方: Onconic Therapeutics Inc.

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT06756074

Reinforced Pancreaticojejunostomy With or Without glubran2

适用疾病: Pancreatic Fistula；Pancreas Cancer；Periampullary Carcinoma
干预: Reinforced pancreaticojejunostomy with tissue adhesive glue modified cyanoacrylate (glubran 2)，Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)
地点: Egypt
申办方: Minia University

即将招募 Phase 3 药物

clinicaltrials.gov NCT07445295

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma
干预: Chiauranib，Toripalimab Injection，Albumin-paclitaxel Injection，Gemcitabine Injection
地点: China
申办方: Chipscreen Biosciences, Ltd.

正在招募 Phase 1, Phase 2 药物手术/操作

clinicaltrials.gov NCT05688215

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

适用疾病: Borderline Resectable Pancreatic Adenocarcinoma；Locally Advanced Pancreatic Ductal Adenocarcinoma
干预: Biospecimen Collection，Computed Tomography，Core Biopsy，Fluorouracil
地点: United States
申办方: Jonsson Comprehensive Cancer Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT05472259

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma
干预: Nanoliposomal irinotecan，5 FU，Leucovorin，Oxaliplatin
地点: Belgium
申办方: Belgian Group of Digestive Oncology

即将招募 Phase 2 药物

clinicaltrials.gov NCT05562297

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

适用疾病: Pancreatic Cancer, Stage IB；Pancreatic Cancer, Stage IIA；Pancreatic Cancer, Stage IIB
干预: sintilimab，nab-paclitaxel，gemcitabine
地点: China
申办方: Shanghai Zhongshan Hospital

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT03740256

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

适用疾病: Bladder Cancer；Head and Neck Squamous Cell Carcinoma；Cancer of the Salivary Gland
干预: CAdVEC
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 药物

clinicaltrials.gov NCT06778863

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Metastatic Solid Tumor
干预: CLSP-1025
地点: United States
申办方: Clasp Therapeutics, Inc.

正在招募 EARLY / Phase 1 生物制剂

clinicaltrials.gov NCT06937567

CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors

适用疾病: Biliary Tract Cancer；Colorectal Carcinoma；Gastric Cancer, Metastatic
干预: CDH17 CAR-T，FAST LACO-Stim CDH17 CAR-T
地点: China
申办方: Zhejiang University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07114861

The KN510713 Study in Combination With mFOLFIRINOX

适用疾病: Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
干预: Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX，Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX
地点: South Korea
申办方: New Cancer Cure-Bio Co.,Ltd.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06943521

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

适用疾病: Head and Neck Squamous Cell Carcinoma (HNSCC)；Non-small Cell Lung Cancer (NSCLC)；Esophageal Cancer
干预: MT-4561
地点: United States，Japan
申办方: Tanabe Pharma America, Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05482893

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

适用疾病: Gastric or Gastroesophageal Junction Adenocarcinoma；Pancreatic Ductal Adenocarcinoma；Biliary Tract Cancer (BTC)
干预: Spevatamig (PT886)，Paclitaxel，Gemcitabine，Abraxane
地点: United States
申办方: Phanes Therapeutics

正在招募 Phase 2 药物

clinicaltrials.gov NCT06145074

Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.

适用疾病: Pancreatic Cancer；Surgery
干预: Propranolol，Placebo
地点: Denmark
申办方: Zealand University Hospital

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT02830724

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

适用疾病: Pancreatic Cancer；Renal Cell Cancer；Breast Cancer
干预: Cyclophosphamide，Fludarabine，Aldesleukin，Anti-hCD70 CAR transduced PBL
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT07306286

Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

适用疾病: Pancreatic Adenocarcinoma Locally Advanced
干预: Cryoablation，Dual-Function Antibody PD-1/CTLA-4
地点: China
申办方: Ruijin Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT07101679

A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer

适用疾病: Locally Advanced Pancreatic Ductal Adenocarcinoma
干预: LICSBR
地点: China
申办方: West China Hospital

正在招募 Phase 2 诊断检测药物

clinicaltrials.gov NCT07096362

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma；Pancreatic Ductal Adenocarcinoma
干预: 5-Fluorouracil，Oxaliplatin，Leucovorin，Irinotecan
地点: United States
申办方: University of Miami

正在招募 Phase 1 药物

clinicaltrials.gov NCT07377045

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

适用疾病: Pancreatic Adenocarcinoma Metastatic
干预: OMTX705，Nab-paclitaxel + Gemcitabine，Tislelizumab (i.v. 200mg)
地点: United States，Spain
申办方: Oncomatryx Biopharma S.L.

即将招募 Phase 2 药物

clinicaltrials.gov NCT07301229

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)
干预: HLX43 DOSE 1 (2.5 mg/kg)，HLX43 DOSE 2 (3.0 mg/kg)
地点: 未列出
申办方: Shanghai Henlius Biotech

正在招募 Phase 2, Phase 3 药物其他

clinicaltrials.gov NCT05254171

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

适用疾病: Pancreatic Cancer Metastatic；Pancreatic Ductal Adenocarcinoma；Pancreatic Cancer Stage IV
干预: SBP-101，Nab-paclitaxel，Gemcitabine，Placebo
地点: United States，Australia，Austria，Belgium 等 6 个
申办方: Panbela Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物手术/操作

clinicaltrials.gov NCT07214298

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma；Stage IV Pancreatic Cancer AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Fluorouracil
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1 药物

clinicaltrials.gov NCT06882746

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

适用疾病: Colorectal Carcinoma；Gastric Carcinoma；Pancreatic Ductal Adenocarcinoma
干预: BI 765049
地点: United States
申办方: Boehringer Ingelheim

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06904378

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma
干预: ONT01，Gemcitabine，Nab paclitaxel
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1 药物放疗

clinicaltrials.gov NCT06141031

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

适用疾病: Pancreatic Cancer
干预: TTI-101，Stereotactic body radiation therapy
地点: United States
申办方: Washington University School of Medicine

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT06349278

Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX

适用疾病: Pancreas Adenocarcinoma；Pancreas Metastases；Pancreas Cancer
干预: Pancreatic resection and non-anatomic liver resections.
地点: Canada
申办方: Laval University

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT03080974

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

适用疾病: Pancreatic Adenocarcinoma
干预: Nivolumab，Irreversible Electroporation
地点: United States
申办方: University of Louisville

正在招募 Phase 2 药物

clinicaltrials.gov NCT04452461

Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery

适用疾病: Pancreatic Adenocarcinoma
干预: mFOLFIRINOX，Gemcitabine / Nab-paclitaxel
地点: Canada
申办方: Hamilton Health Sciences Corporation

正在招募 Phase 2 药物

clinicaltrials.gov NCT04683315

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

适用疾病: Pancreatic Cancer
干预: mFOLFIRINOX Treatment Regimen，Gemcitabine/Nab-paclitaxel Treatment Regimen
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 2 药物

clinicaltrials.gov NCT05093231

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: Pembrolizumab，Olaparib
地点: Australia，United Kingdom
申办方: Cambridge University Hospitals NHS Foundation Trust

即将招募阶段未标明放疗

clinicaltrials.gov NCT06272162

Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: MR guided radiotherapy
地点: Netherlands
申办方: UMC Utrecht

正在招募 Phase 1 药物

clinicaltrials.gov NCT06917079

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

适用疾病: Non-Small Cell Lung Cancer；NSCLC；PDAC - Pancreatic Ductal Adenocarcinoma
干预: BBO-11818，Pembrolizumab，Platinum chemotherapy (cisplatin or carboplatin)，Pemetrexed
地点: United States，Australia
申办方: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

正在招募阶段未标明器械放疗

clinicaltrials.gov NCT05679674

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

适用疾病: Pancreas Cancer；Locally Advanced；Locally Advanced Pancreatic Adenocarcinoma
干预: Stereotactic Ablative Body Radiation (SABR)，Tumor Treating Fields (TTF)
地点: United States
申办方: Baptist Health South Florida

即将招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT07627191

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

适用疾病: Pancreatic Cancer；Colorectal Cancer；Hepatocellular Carcinoma
干预: GLP1-RA (semaglutide)
地点: United States
申办方: University of Arizona

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT06989437

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

适用疾病: Cachexia；Metastatic Pancreatic Ductal Adenocarcinoma
干预: ponsegromab，placebo
地点: United States，Australia，Belgium，Brazil 等 17 个
申办方: Pfizer

正在招募 Phase 1, Phase 2 药物放疗

clinicaltrials.gov NCT07595172

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Locally Advanced and Metastatic Pancreatic Cancer
干预: NALIRIFOX+Adebrelimab，PULSAR
地点: China
申办方: West China Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT07671339

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: ELI-002 7P，Tislelizumab，mFOLFIRINOX
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT07594964

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors

适用疾病: Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)；Pancreatic Ductal Adenocarcinoma (PDAC)；Hepatocellular Carcinoma (HCC)
干预: XH001 Injection，mFOLFIRINOX Treatment Regimen
地点: China
申办方: Shenzhen Xinhe Biomedical

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07148128

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

适用疾病: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma；Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer；Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
干预: WEF-001
地点: United States，Canada，United Kingdom
申办方: Auricula Biosciences Inc.

正在招募 Phase 3 药物

clinicaltrials.gov NCT01954992

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

适用疾病: Metastatic Pancreatic Adenocarcinoma
干预: Glufosfamide，Fluorouracil
地点: United States
申办方: Eleison Pharmaceuticals LLC.

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT05877599

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

适用疾病: Non-small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Colorectal Carcinoma
干预: Autologous, engineered T Cells targeting TP53 R175H
地点: United States
申办方: AstraZeneca

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07475234

Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma
干预: Rimegepant plus Nab-Paclitaxel and Gemcitabine
地点: 未列出
申办方: Xiuchao Wang

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07223047

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

适用疾病: Advanced Solid Malignancies；Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)
干预: BMS-986523，Gemcitabine，Nab-Paclitaxel，Cetuximab
地点: United States，Canada，Spain
申办方: Bristol-Myers Squibb

正在招募 Phase 1, Phase 2 联合产品

clinicaltrials.gov NCT04605913

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

适用疾病: Pancreas Cancer；Metastatic Pancreatic Cancer；Pancreatic Adenocarcinoma
干预: Modified GCN+TTF treatment
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物

clinicaltrials.gov NCT07483554

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

适用疾病: CLDN18.2 Positive；Gastric/Gastroesophageal Junction Adenocarcinoma；Pancreatic Ductal Adenocarcinoma
干预: IBI343,Gemcitabine, Albumin-bound Paclitaxel
地点: China
申办方: Innovent Biologics (Suzhou) Co. Ltd.

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT06821997

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

适用疾病: Borderline Resectable Pancreatic Ductal Adenocarcinoma
干预: Biospecimen Collection，Computed Tomography，Fluorouracil，Irinotecan Sucrosofate
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT04665947

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

适用疾病: Metastatic Pancreatic Cancer；Locally Advanced Pancreatic Adenocarcinoma
干预: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
地点: United States
申办方: University of California, Davis

正在招募 Phase 1 药物

clinicaltrials.gov NCT06026410

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

适用疾病: Solid Tumors With HRAS Alterations；Non Small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)
干预: Darlifarnib，Cabozantinib，Adagrasib
地点: United States，France，Germany，Italy 等 1 个
申办方: Kura Oncology, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06941857

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: Oxaliplatin，Irinotecan，Folinic Acid，5-Fluorouracil (5-FU)
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

即将招募 Phase 1, Phase 2 联合产品

clinicaltrials.gov NCT07477418

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Borderline Resectable Pancreatic Cancer；Pancreatic Neoplasms
干预: Gemcitabine Delivered by Transarterial Microperfusion
地点: United States
申办方: University of Vermont

正在招募 Phase 1 药物

clinicaltrials.gov NCT06040541

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: RMC-9805，RMC-6236
地点: United States
申办方: Revolution Medicines, Inc.

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT06065891

Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer

适用疾病: Pancreas Cancer；Pancreas Adenocarcinoma；Lymph Node Metastasis
干预: PALN resection
地点: Denmark，Sweden
申办方: Jon Unosson

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT06423326

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

适用疾病: Borderline Resectable Pancreatic Ductal Adenocarcinoma；Resectable Pancreatic Adenocarcinoma；Stage I Pancreatic Cancer AJCC v8
干预: Biopsy，Biospecimen Collection，Cisplatin，Computed Tomography
地点: United States
申办方: Emory University

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT07627711

Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)；Unresectable Locally Advanced；Metastatic Disease
干预: EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)，EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)，Lymphodepleting chemotherapy (Flu/Cy)
地点: China
申办方: Beijing Biotech

正在招募阶段未标明放疗

clinicaltrials.gov NCT04881487

Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy

适用疾病: Recurrent Pancreatic Ductal Adenocarcinoma
干预: Additional stereotactic body radiation therapy
地点: Netherlands
申办方: UMC Utrecht

正在招募 Phase 2 药物

clinicaltrials.gov NCT06816914

Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

适用疾病: Resectable Pancreatic Adenocarcinoma
干预: NALIRIFOX
地点: Taiwan
申办方: Taichung Veterans General Hospital

正在招募阶段未标明放疗

clinicaltrials.gov NCT05837767

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

适用疾病: Invasive Ductal Breast Carcinoma；Invasive Ductal Breast Carcinoma Stage IV；Lobular Breast Carcinoma
干预: Palliative radiotherapy
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

即将招募 Phase 1 药物

clinicaltrials.gov NCT07348107

ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

适用疾病: Advanced Pancreatic Ductal Adenocarcinoma
干预: ATRA，Arsenic Trioxide (ATO)，Gemcitabine，Nab-paclitaxel
地点: Canada
申办方: Daniel Breadner

正在招募 Phase 2 药物

clinicaltrials.gov NCT06895031

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

适用疾病: Solid Tumor；Pancreatic Ductal Adenocarcinoma (PDAC)；Non-small Cell Lung Cancer (NSCLC)
干预: JYP0015
地点: China
申办方: Guangzhou JOYO Pharma Co., Ltd

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT03608631

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

适用疾病: KRAS NP_004976.2:p.G12D；Metastatic Pancreatic Adenocarcinoma；Pancreatic Ductal Adenocarcinoma
干预: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

clinicaltrials.gov NCT04325425

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

适用疾病: Neuroendocrine Carcinoma
干预: FOLFOXIRI Protocol，Cisplatin injection
地点: France
申办方: Centre Hospitalier Universitaire Dijon

正在招募 Phase 3 药物

clinicaltrials.gov NCT05477576

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

适用疾病: GEP-NET；Gastroenteropancreatic Neuroendocrine Tumor；Gastroenteropancreatic Neuroendocrine Tumor Disease
干预: RYZ101，Everolimus，Sunitinib，Octreotide
地点: United States，Belgium，Brazil，Canada 等 4 个
申办方: RayzeBio, Inc.

正在招募阶段未标明生物制剂

clinicaltrials.gov NCT06141369

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

适用疾病: Adrenal Cortical Carcinoma；Medullary Thyroid Cancer；Thymic Neuroendocrine Carcinoma
干预: individualized mRNA neoantigen vaccine (mRNA-0523-L001)
地点: China
申办方: Shanghai Jiao Tong University School of Medicine

即将招募 Phase 2 药物其他

clinicaltrials.gov NCT07028424

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

适用疾病: PDAC - Pancreatic Ductal Adenocarcinoma
干预: Nal-IRI，Ciprofloxacin，Paclitaxel，Gemcitabine
地点: France
申办方: GERCOR - Multidisciplinary Oncology Cooperative Group

正在招募 Phase 2 药物

clinicaltrials.gov NCT06219941

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

适用疾病: Gastric Cancer；Gastroesophageal Junction Cancer；Biliary Tract Cancer
干预: AZD0901，5-Fluorouracil，Leucovorin，l-leucovorin
地点: United States，Australia，Canada，China 等 10 个
申办方: AstraZeneca

正在招募 Phase 3 药物

clinicaltrials.gov NCT07522073

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

适用疾病: Solid Tumors
干预: INCB161734，Placebo，Investigator's choice of chemotherapy
地点: United States，Australia，Austria，Belgium 等 16 个
申办方: Incyte Corporation

正在招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT07594067

TCR1188-ABC Cells in KRAS-mutated Cancers

适用疾病: Cholangiocarcinoma；Colorectal Cancer；Non-Small Cell Lung Cancer
干预: TCR1188-ABC cells，Fludarabine + Cyclophosphamide combination，Tocilizumab
地点: United States
申办方: University of Pennsylvania

正在招募 Phase 2 放疗

clinicaltrials.gov NCT06453486

A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment

适用疾病: Locally Advanced Pancreatic Adenocarcinoma
干预: High dose radiation therapy
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

适用疾病: Pancreatic Ductal Adenocarcinoma；Gastric Cancer；Esophageal Cancer
干预: [203Pb]Pb-PSV359，[212Pb]Pb-PSV359
地点: United States
申办方: Perspective Therapeutics

正在招募 Phase 3 药物

clinicaltrials.gov NCT07491445

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

适用疾病: Pancreatic Cancer；Pancreatic Cancer Metastatic；PDAC
干预: daraxonrasib，gemcitabine，nab-paclitaxel
地点: United States，Japan
申办方: Revolution Medicines, Inc.

即将招募 Phase 2 药物

clinicaltrials.gov NCT07623642

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

适用疾病: Uterine Cervical Neoplasms；Triple Negative Breast Neoplasms；Prostatic Neoplasms
干预: GV20-0251，anti-PD-1 monoclonal antibodies
地点: China
申办方: GV20 Therapeutics

正在招募 Phase 3 药物

clinicaltrials.gov NCT06897644

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

适用疾病: Pancreatic Adenocarcinoma Advanced or Metastatic
干预: Oxaliplatin，Irinotecan (CPT-11)，Leucovorin，5-FU (5-fluorouracil)
地点: Italy
申办方: Gruppo Oncologico del Nord-Ovest

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT06801899

ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer

适用疾病: Pancreatic Cancer
干预: Total pancreatectomy (TP)，Partial pancreaticoduodenectomy (PD)
地点: Germany，Switzerland
申办方: Insel Gruppe AG, University Hospital Bern

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07504263

Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies

适用疾病: Advanced Malignancies；Oncology；Colorectal Cancer
干预: RP-001
地点: 未列出
申办方: Recurv Pharma Inc

正在招募 Phase 2 药物

clinicaltrials.gov NCT07303465

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

适用疾病: KRAS G12D Mutations；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: RNK08954
地点: China
申办方: Ranok Therapeutics (Hangzhou) Co., Ltd.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06921928

Study for AZD4360 in Participants With Advanced Solid Tumours

适用疾病: Gastric Cancer；Gastroesophageal Junction Cancer；Biliary Tract Cancer
干预: AZD4360
地点: United States，China，Germany，Japan 等 1 个
申办方: AstraZeneca

正在招募 Phase 1 药物

clinicaltrials.gov NCT07589205

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

适用疾病: Solid Tumor；Colorectal Cancer；Non-small Cell Lung Cancer
干预: Drug: IBI3028
地点: China
申办方: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07163273

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: NALIRIFOX，Gemcitabine plus nab-Paclitaxel (GnP)
地点: United States
申办方: Northwell Health

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06399757

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

适用疾病: Colorectal Cancer；Cholangiocarcinoma；Appendiceal Adenocarcinoma
干预: APL-5125
地点: United States
申办方: Apollo Therapeutics Ltd

正在招募 Phase 2 器械药物

clinicaltrials.gov NCT04990609

EUS-RFA PANCARDINAL-1 Trial

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)
干预: Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)，Neoadjuvant Chemotherapy (NAC)
地点: United States
申办方: The University of Texas Health Science Center, Houston

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07175389

JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure

适用疾病: Refractory Pancreatic Ductal Adenocarcinoma；Refractory Pancreatic Adenocarcinoma
干预: JDB153，Serplulimab
地点: China
申办方: West China Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT04911816

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

适用疾病: Adenocarcinoma of the Pancreas
干预: Hydroxychloroquine sulfate
地点: United States
申办方: West Virginia University

正在招募 Phase 1 药物手术/操作

clinicaltrials.gov NCT03484299

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

适用疾病: Pancreas Cancer
干预: Irreversible Electroporation (IRE)，Gemcitabine，FOLFIRINOX
地点: United States
申办方: University of Louisville

正在招募 Phase 2 生物制剂药物

clinicaltrials.gov NCT05451043

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

适用疾病: Pancreatic Cancer；Hepatocellular Cancer；Biliary Tract Cancer
干预: Durvalumab，Gemcitabine，Nab paclitaxel，Tremelimumab
地点: Canada
申办方: AHS Cancer Control Alberta

正在招募 Phase 1 药物

clinicaltrials.gov NCT06411691

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

适用疾病: Colorectal Cancer；Pancreatic Cancer
干预: KRAS Vaccine with Poly-ICLC adjuvant，Balstilimab，Botensilimab
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 药物

clinicaltrials.gov NCT06756035

CT-95 in Advanced Cancers Associated With Mesothelin Expression

适用疾病: Mesothelin-Expressing Tumors；Epithelial Ovarian Cancer；Malignant Pleural Mesothelioma, Advanced
干预: CT-95
地点: United States
申办方: Context Therapeutics Inc.

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT07232810

Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer

适用疾病: Pancreatic Head Cancer；Pancreatic Ductal Adenocarcinoma
干预: Total Mesopancreas Excision (TMpE)
地点: Egypt
申办方: Minia University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07629960

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

适用疾病: Advanced Solid Tumor；Non-Small Cell Lung Cancer；Colorectal Neoplasms
干预: BLU-924
地点: United States
申办方: Blueprint Medicines Corporation

正在招募 Phase 1 药物

clinicaltrials.gov NCT05208762

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

适用疾病: Carcinoma, Non-Small-Cell Lung；Squamous Cell Carcinoma of the Head and Neck；Esophageal Squamous Cell Carcinoma
干预: PF-08046054，pembrolizumab
地点: United States，Belgium，Canada，China 等 7 个
申办方: Seagen, a wholly owned subsidiary of Pfizer

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07640295

Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

适用疾病: Metastatic Pancreatic Ductal Adenocarcinoma
干预: JAB-23E73 tablet，nab-paclitaxel，gemcitabine
地点: China
申办方: Jacobio Pharmaceuticals Co., Ltd.

正在招募 Phase 1 药物

clinicaltrials.gov NCT07090499

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

适用疾病: Advanced/Metastatic Solid Tumors；Bladder Cancer；Urothelial Carcinoma
干预: PF-08046876
地点: United States，Canada，Puerto Rico，Spain 等 1 个
申办方: Pfizer

即将招募 Phase 2 药物

clinicaltrials.gov NCT07561463

Sacituzumab Tirumotecan for Pancreatic Cancer

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)
干预: Sacituzumab tirumotecan
地点: 未列出
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 1 药物

clinicaltrials.gov NCT06182072

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

适用疾病: Pancreatic Ductal Adenocarcinoma (PDAC)
干预: ProAgio Dose Levels (DL) 1,2,3,4，Gemcitabine, nab paclitaxel
地点: United States
申办方: ProDa BioTech, LLC

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05706129

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

适用疾病: Clear Cell Renal Cell Cancer (ccRCC)；Pancreatic Ductal Adenocarcinoma (PDAC)；Colorectal Cancer (CRC)
干预: [68Ga]Ga-DPI-4452，[177Lu]Lu-DPI-4452
地点: Australia，France
申办方: ITM Oncologics GmbH

正在招募 Phase 1 放疗

clinicaltrials.gov NCT05141513

Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma

适用疾病: Pancreatic Cancer
干预: High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 联合产品

clinicaltrials.gov NCT05919238

Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma

适用疾病: Locally Advanced Unresectable Pancreatic Adenocarcinoma
干预: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
地点: United States
申办方: Impact Biotech Ltd

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT03322995

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

适用疾病: Pancreatic Cancer
干预: First-line Chemotherapy，Second-line Chemotherapy，Chemoradiation
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 2 药物

clinicaltrials.gov NCT06405490

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

适用疾病: Nanoliposomal Irinotecan；Cadonilimab；Oxaliplatin
干预: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 2 药物

clinicaltrials.gov NCT06789679

Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

适用疾病: Pancreatic Adenocarcinoma
干预: Gemcitabine, albumin-bound paclitaxel, S-1，Gemcitabine, albumin-bound paclitaxel
地点: China
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 2 器械药物

clinicaltrials.gov NCT05776524

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer；Metastatic Adenocarcinoma
干预: Nab paclitaxel，Gemcitabine，TheraBionic
地点: United States
申办方: THERABIONIC INC.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06896188

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

适用疾病: Pancreatic Adenocarcinoma
干预: Retifanlimab，Chemotherapy，9-ING-41
地点: United States
申办方: Anwaar Saeed

正在招募 Phase 2 药物

clinicaltrials.gov NCT07076212

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

适用疾病: Metastatic Pancreatic Adenocarcinoma；Locally Advanced Pancreatic Adenocarcinoma
干预: Liposomal Irinotecan，Oxaliplatin，5-Fluorouracil，Leucovorin
地点: United States
申办方: Medical University of South Carolina

正在招募 Phase 2 器械药物

clinicaltrials.gov NCT06831136

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Neoadjuvant Chemotherapy (NAC)，Immunotherapy (pembrolizumab)，Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)
地点: United States
申办方: The University of Texas Health Science Center, Houston

正在招募 Phase 3 药物放疗

clinicaltrials.gov NCT06250972

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

适用疾病: Pancreatic Adenocarcinoma
干预: Gemcitabine, Nab-paclitaxel, Irinotecan，Intensity-Modulated Radiation Therapy (IMRT)
地点: China
申办方: Fudan University

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06723236

A Study of MGC028 in Participants With Advanced Solid Tumors

适用疾病: Advanced Solid Tumors；NSCLC Adenocarcinoma；Cholangiocarcinoma
干预: MGC028
地点: United States
申办方: MacroGenics

正在招募 Phase 1 联合产品药物

clinicaltrials.gov NCT06447662

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

适用疾病: Carcinoma, Pancreatic Ductal；Colorectal Neoplasms；Carcinoma, Non-Small-Cell Lung
干预: PF-07934040，Gemcitabine，Nab-paclitaxel，Cetuximab
地点: United States，China，Puerto Rico
申办方: Pfizer

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT04157127

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

适用疾病: Pancreatic Adenocarcinoma；Pancreatic Cancer；Pancreatic Adenosquamous Carcinoma
干预: Autologous DC Therapy
地点: United States
申办方: Diakonos Oncology Corporation

正在招募 Phase 2 生物制剂药物手术/操作

clinicaltrials.gov NCT07226856

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

适用疾病: Metastatic Pancreatic Adenocarcinoma；Recurrent Pancreatic Adenocarcinoma；Stage IV Pancreatic Cancer AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Gemcitabine
地点: United States
申办方: Mayo Clinic

即将招募 Phase 2 联合产品

clinicaltrials.gov NCT06573398

Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC

适用疾病: Carcinoma, Pancreatic Ductal
干预: SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin
地点: 未列出
申办方: Ruijin Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06747845

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

适用疾病: Pancreatic Adenocarcinoma Metastatic
干预: Niraparib，FOLFIRI，Ipilimumab
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

即将招募 Phase 1, Phase 2 药物放疗

clinicaltrials.gov NCT06345599

PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)

适用疾病: Pancreatic Ductal Adenocarcinoma
干预: Radiotherapy，Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab，Chemotherapy:Albumin-bound paclitaxel、Gemcitabine
地点: 未列出
申办方: Second Affiliated Hospital of Soochow University

正在招募 Phase 2 药物

clinicaltrials.gov NCT04543071

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

适用疾病: Pancreatic Cancer；Adenocarcinoma of the Pancreas；Adenocarcinoma
干预: Motixafortide，Cemiplimab，Gemcitabine，Nab paclitaxel
地点: United States
申办方: Gulam Manji

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06782932

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: AGEN2373，Balstilimab，Cyclophosphamide，GVAX
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT05268692

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

适用疾病: Pancreatic Adenocarcinoma
干预: GS，GnP
地点: Japan
申办方: Kochi University

正在招募 Phase 1 药物

clinicaltrials.gov NCT07458347

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

适用疾病: KRAS-mutant Non-small Cell Lung Cancer (NSCLC)；KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)；KRAS-mutant Colorectal Cancer (CRC)
干预: KST-6051
地点: United States
申办方: Kestrel Therapeutics, Inc.

正在招募阶段未标明手术/操作

clinicaltrials.gov NCT04037007

Efficacy of Fistulotomy for Biliary Cannulation

适用疾病: Cholangiocarcinoma；Choledocholithiasis; Cholangitis；Pancreatic Cancer
干预: Fistulotomy - High experienced.，Fistulotomy - Low experienced.，Conventional (guidewire) cannulation- High experienced，Conventional (guidewire) cannulation - Low experienced
地点: Mexico
申办方: Coordinación de Investigación en Salud, Mexico

即将招募 Phase 1, Phase 2 生物制剂药物手术/操作

clinicaltrials.gov NCT07619521

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

适用疾病: Advanced Pancreatic Ductal Adenocarcinoma；Metastatic Pancreatic Ductal Adenocarcinoma；Stage III Pancreatic Cancer AJCC v8
干预: Biospecimen Collection，Diagnostic Imaging Testing，Echocardiography Test，Multigated Acquisition Scan
地点: 未列出
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT07126158

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

适用疾病: Pancreatic Adenocarcinoma；Cancer of the Pancreas；Pancreas Cancer
干预: Stereotactic body radiotherapy，Defactinib，Avutometinib
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06005493

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

适用疾病: Gastric Cancer；Gastro-esophageal Junction Cancer；Pancreatic Ductal Adenocarcinoma
干预: AZD5863
地点: United States，China，France，Japan 等 4 个
申办方: AstraZeneca

即将招募 Phase 1 器械药物

clinicaltrials.gov NCT07314385

NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer

适用疾病: Pancreatic Adenocarcinoma Metastatic；Liver Metastasis
干预: nanoliposomal irinotecan+5-FU+leucovorin，NH002 (Perflutren Lipid Microspheres) Injectable Suspension，Aco Apache Ultrasound
地点: Taiwan
申办方: National Taiwan University Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT05277766

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

适用疾病: Peritoneal Carcinomatosis；Peritoneal Metastases；Colorectal Cancer
干预: PIPAC with Nal-IRI
地点: Belgium
申办方: University Hospital, Ghent

正在招募 Phase 2 器械药物

clinicaltrials.gov NCT06576115

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

适用疾病: Metastatic Pancreatic Adenocarcinoma
干预: Nab paclitaxel，Gemcitabine，TheraBionic P1
地点: United States
申办方: Barbara Ann Karmanos Cancer Institute

正在招募 Phase 2 药物

clinicaltrials.gov NCT04115163

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

适用疾病: Metastatic Pancreatic Adenocarcinoma；Stage IV Pancreatic Cancer AJCC v8
干预: Gemcitabine，Nab-paclitaxel
地点: United States
申办方: Anne Noonan

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT05462496

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: Biopsy，FOLFIRINOX，Ciprofloxacin，Metronidazole
地点: United States
申办方: Icahn School of Medicine at Mount Sinai

正在招募 Phase 1 药物

clinicaltrials.gov NCT07066657

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

适用疾病: Locally Advanced or Metastatic Solid Tumors；Colorectal Cancer；Gastric Cancer
干预: MRG007
地点: United States，China
申办方: ArriVent BioPharma, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT03915678

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

适用疾病: Solid Tumor, Adult；Pancreatic Cancer；Virus-associated Tumors
干预: Association atezolizumab + BDB001 + RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001 + RT
地点: France
申办方: Institut Bergonié

即将招募 Phase 2 药物

clinicaltrials.gov NCT06916975

Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer Non-resectable；Pancreatic Cancer Metastatic
干预: Adebrelimab，AG
地点: China
申办方: Jin Xu

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06662669

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

适用疾病: Metastatic Pancreatic Cancer
干预: YL-13027，HY-0102，Gemcitabine，Nab-paclitaxel
地点: 未列出
申办方: Shanghai YingLi Pharmaceutical Co. Ltd.

正在招募 Phase 2 药物

clinicaltrials.gov NCT05859750

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: AK104，AK104，Gemcitabine，Nab-Paclitaxel
地点: China
申办方: Akeso

即将招募 Phase 2 药物

clinicaltrials.gov NCT06759090

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

适用疾病: Metastatic Pancreatic Carcinoma
干预: Metronomic capecitabine，Camrelizumab，Apatinib Mesylate Tablets
地点: China
申办方: Zhejiang University

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT06361888

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

适用疾病: Metastatic Pancreatic Cancer
干预: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine，Nab-paclitaxel Plus Gemcitabine，Surufatinib with Nab-paclitaxel, and Gemcitabine
地点: China
申办方: Hutchmed

正在招募 Phase 2 药物

clinicaltrials.gov NCT06078787

Olaparib in PALB2 Advanced Pancreatic Cancer

适用疾病: Advanced Pancreatic Cancer；Metastatic Pancreatic Cancer
干预: Olaparib 150 MG
地点: Italy
申办方: Azienda Ospedaliero-Universitaria di Modena

正在招募 Phase 2 药物

clinicaltrials.gov NCT06008288

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

适用疾病: KRAS P.G12C；Pancreatic Cancer；Solid Tumor
干预: JAB-21822
地点: China
申办方: Allist Pharmaceuticals, Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07589569

An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: HRS-7058
地点: China
申办方: Shandong Suncadia Medicine Co., Ltd.

正在招募 Phase 3 药物

clinicaltrials.gov NCT07238283

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

适用疾病: First-line Treatment of Metastatic Pancreatic Cancer
干预: Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate，nab-paclitaxel; gemcitabine
地点: China
申办方: Jiangsu HengRui Medicine Co., Ltd.

正在招募 Phase 3 药物

clinicaltrials.gov NCT06752811

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer Metastatic
干预: paclitaxel polymeric micelles for injection，Gemcitabine Hydrochloride for Injection，Paclitaxel for Injection (albumin bound )，Gemcitabine Hydrochloride for Injection
地点: China
申办方: Shanghai Yizhong Pharmaceutical Co., Ltd.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06663072

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

适用疾病: Metastatic Pancreatic Neuroendocrine Tumor
干预: Fulvestrant，177Lu-DOTATATE
地点: United States
申办方: University of Chicago

正在招募 Phase 2 药物放疗

clinicaltrials.gov NCT06491472

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: Ivonescimab，Gemcitabine，Nab paclitaxel，SBRT
地点: China
申办方: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

即将招募 Phase 2 药物

clinicaltrials.gov NCT03301805

A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: BLEX 404
地点: 未列出
申办方: Rgene Corporation

即将招募 Phase 2 药物

clinicaltrials.gov NCT06255912

Clinical Trial for Advanced or Metastatic Pancreatic Cancer

适用疾病: Pancreas Cancer
干预: LTC004 + MIL-97，LTC004 + MIL-97+chemotherapy
地点: 未列出
申办方: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

正在招募 Phase 2 联合产品

clinicaltrials.gov NCT06946901

The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial

适用疾病: Hyperthermic Intraperitoneal Chemotherapy；Peritoneal Metastatic Pancreatic Cancer
干预: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin + Systemic AG Chemotherapy
地点: China
申办方: Shanghai Zhongshan Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06761027

mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer

适用疾病: Locally Advanced Pancreatic Cancer；Metastatic Pancreatic Cancer
干预: Anlotinib combined with Sintilimab
地点: China
申办方: Fujian Provincial Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT06953999

A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine，Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine，Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine
地点: China
申办方: Akeso

即将招募 Phase 3 药物其他

clinicaltrials.gov NCT07272109

Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes

适用疾病: Pancreatic Cancer
干预: Nab-paclitaxel，Gemcitabine (1000 mg/m2)，Anti-Diabetics，Active treatment and monitoring
地点: China
申办方: Fudan University

即将招募 Phase 1, Phase 2 药物手术/操作

clinicaltrials.gov NCT07594626

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

适用疾病: Metastatic Biliary Tract Carcinoma；Metastatic Colon Carcinoma；Metastatic Esophageal Carcinoma
干预: Biospecimen Collection，Computed Tomography，Pemetrexed，PRMT5 Inhibitor BMS-986504
地点: United States
申办方: Northwestern University

即将招募阶段未标明器械手术/操作

clinicaltrials.gov NCT07191418

Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors

适用疾病: Pancreatic Cancer Metastatic to Liver
干预: Habib™ EndoHPB，ERCP
地点: Sweden
申办方: Roberto Valente

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06454448

Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

适用疾病: Adebrelimab (SHR-1316)；Decitabine；Metastatic Pancreatic Cancer
干预: Adebrelimab;decitabine;
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06244771

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

适用疾病: Advanced Solid Tumors With KRAS G12C Mutations；Solid Tumor, Adult；Unresectable Solid Tumor
干预: FMC-376
地点: United States，Australia，South Korea
申办方: Frontier Medicines Corporation

即将招募 Phase 2 药物

clinicaltrials.gov NCT05637567

Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head

适用疾病: Pancreatic Cancer Resectable
干预: Acetylsalicylic acid，Placebo
地点: 未列出
申办方: German Cancer Research Center

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT05141149

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: PBP1510 (400mg/16mL)，Gemcitabine (1000 mg/m^2)
地点: United States，Australia，Singapore，Spain
申办方: Prestige Biopharma Limited

即将招募 Phase 2 药物

clinicaltrials.gov NCT04901741

Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

适用疾病: Metastatic Pancreatic Cancer
干预: Olaptesed pegol，Pembrolizumab
地点: 未列出
申办方: TME Pharma AG

即将招募 EARLY / Phase 1 生物制剂

clinicaltrials.gov NCT07231094

A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer Metastatic
干预: SapDM275 Tumor Vaccine Injection
地点: China
申办方: The Third Xiangya Hospital of Central South University

正在招募 Phase 2 联合产品

clinicaltrials.gov NCT05065801

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

适用疾病: Metastatic Pancreatic Cancer
干预: GEMBRAX/FOLFIRINOX Arm A，FOLFIRINOX Arm B
地点: France
申办方: Institut du Cancer de Montpellier - Val d'Aurelle

正在招募 Phase 2 药物

clinicaltrials.gov NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

适用疾病: Advanced Solid Tumor；Melanoma；Head and Neck Cancer
干预: HER3-DXd
地点: United States，Australia，Belgium，Canada 等 12 个
申办方: Daiichi Sankyo

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07342725

Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer Metastatic
干预: IBI363 + chemotherapy
地点: 未列出
申办方: Ruijin Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06770452

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

适用疾病: Metastatic Pancreatic Carcinoma
干预: HRS-4642，Nimotuzumab，gemcitabine + nab-paclitaxel
地点: China
申办方: Zhejiang University

即将招募 Phase 1 药物

clinicaltrials.gov NCT06614751

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

适用疾病: Solid Cancers；BRCA Mutation；HRD Cancer
干预: DAT-2645 tablet，DAT-2645 tablet
地点: China
申办方: Danatlas Pharmaceuticals Co., Ltd

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07040228

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

适用疾病: Pancreatic Cancer Metastatic
干预: Regorafenib combined with Toripalimab and Albumin paclitaxel
地点: China
申办方: Junjie Hang

正在招募 Phase 4 药物

clinicaltrials.gov NCT05035147

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: albumin-bound paclitaxel
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06767813

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

适用疾病: Pancreatic Neoplasms
干预: TQB2868 injection，Gemcitabine injection，Albumin paclitaxel injection，Anlotinib capsules
地点: China
申办方: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

正在招募阶段未标明药物

clinicaltrials.gov NCT06539806

Clinical Study Evaluating the Effect of Losartan

适用疾病: Pancreatic Cancer
干预: Losartan 50mg Tab
地点: Egypt
申办方: Tanta University

正在招募 Phase 1 药物

clinicaltrials.gov NCT06278454

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases

适用疾病: Unresectable Pancreatic Cancer；Advanced Pancreatic Cancer；Lymph Node Metastases
干预: NRT6008 Injection + Systematic chemotherapy
地点: China
申办方: Chengdu New Radiomedicine Technology Co. LTD.

正在招募 Phase 3 手术/操作

clinicaltrials.gov NCT06391892

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

适用疾病: Pancreatic Cancer；Circulating Tumor Cell；Predictive Cancer Model
干预: Neoadjuvant chemotherapy instead of upfront surgery，Upfront surgery
地点: Austria
申办方: Elisabethinen Hospital

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT06906562

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

适用疾病: Advanced Pancreatic Carcinoma；Metastatic Pancreatic Carcinoma；Stage II Pancreatic Cancer AJCC v8
干预: Pemigatinib，Computed Tomography (CT)，Magnetic Resonance Imaging，Optical Coherence Tomography
地点: United States
申办方: Sameek Roychowdhury

正在招募 Phase 2 生物制剂药物手术/操作

clinicaltrials.gov NCT06202066

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

适用疾病: Digestive System Neuroendocrine Neoplasm；Lung Neuroendocrine Neoplasm；Malignant Solid Neoplasm
干预: Biospecimen Collection，Computed Tomography，Incomplete Freund''s Adjuvant，Magnetic Resonance Imaging
地点: United States
申办方: Roswell Park Cancer Institute

即将招募 Phase 2 药物

clinicaltrials.gov NCT07631884

Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor

适用疾病: Solid Tumors；Neoplasms (Cancer / Tumors)；Advanced Malignant Solid Neoplasm
干预: Trastuzumab Rezetecan
地点: 未列出
申办方: Haihua Yuan

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06479239

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

适用疾病: Pancreas Cancer；Pancreatic Cancer
干预: EGFR FPBMC
地点: United States
申办方: University of Virginia

正在招募阶段未标明药物手术/操作

clinicaltrials.gov NCT05869474

Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma

适用疾病: Metastatic Pancreatic Cancer
干预: Iodine125-Seeds implantation，Gem/nab-P Chemotherapy
地点: China
申办方: Changhai Hospital

即将招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07539155

Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

适用疾病: Borderline Resectable/Unresectable Pancreatic Cancer；Non Metastatic Pancreatic Cancer
干预: Intratumoral MMR Injection
地点: 未列出
申办方: University of Arkansas

正在招募 Phase 1 药物

clinicaltrials.gov NCT06440005

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

适用疾病: Cancer；Advanced Cancer；Locally Advanced Carcinoma
干预: AGX101
地点: United States
申办方: Angiex, Inc.

即将招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06513455

Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: Irinotecan liposome（40mg/m2），Nab-paclitaxel，Gemcitabine，Irinotecan Liposome（60mg/m2）
地点: 未列出
申办方: Harbin Medical University

正在招募 Phase 2 药物

clinicaltrials.gov NCT05929885

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

适用疾病: Metastatic Pancreatic Cancer
干预: Low Dose OXIRI (LD-OXIRI)
地点: Singapore
申办方: National Cancer Centre, Singapore

正在招募 Phase 3 药物

clinicaltrials.gov NCT07262567

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

适用疾病: Metastatic Pancreatic Cancer
干预: GFH375，Chemotherapy
地点: China
申办方: Genfleet Therapeutics (Shanghai) Inc.

正在招募 Phase 2 药物

clinicaltrials.gov NCT06584227

Adebrelimab and Chidamide for Pancreatic Cancer

适用疾病: Pancreatic Cancer, Adult
干预: Adebrelimab and Chidamide Combined with Gemcitabine and S1
地点: China
申办方: Liu Xiufeng

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06572813

Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer

适用疾病: Pancreas Cancer
干预: Bortezomib Injection，Sintilimab，mFOLFIRINOX
地点: China
申办方: Zhejiang University

即将招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT06888648

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

适用疾病: Pancreatic Cancer Metastatic；Pancreatic Cancer Non-resectable
干预: individualized anti-tumor new antigen iNeo-Vac-R01 injection，mFOLFIRINOX Treatment Regimen，Sintilimab injection
地点: China
申办方: Zhejiang University

正在招募 Phase 2 药物

clinicaltrials.gov NCT07504471

Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases

适用疾病: Pancreatic Neoplasms；Hepatic Metastasis of Pancreatic Cancer
干预: pH-NASOX-Immune Group
地点: China
申办方: Ruijin Hospital

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07030257

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

适用疾病: Solid Tumor Malignancies；Colorectal Carcinoma；Small Cell Lung Cancer ( SCLC )
干预: CP-383
地点: United States
申办方: Tasca Therapeutics

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07066995

Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer

适用疾病: Pancreatic Cancer；Pancreatic Carcinoma；Pancreatic Cancer Non-resectable
干预: Mesothelin and Claudin 18.2 CAR-T cells
地点: China
申办方: Essen Biotech

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT04550494

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Castration-Resistant Prostate Carcinoma
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

clinicaltrials.gov NCT06465069

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

适用疾病: Metastatic Solid Tumor；Recurrent Solid Tumor；Advanced Solid Tumor
干预: LY4052031
地点: United States，Australia，China，France 等 4 个
申办方: Eli Lilly and Company

即将招募 Phase 3 药物

clinicaltrials.gov NCT07232875

HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

适用疾病: KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
干预: HRS-4642 + AG，HRS-4642 placebo + AG
地点: China
申办方: Jiangsu HengRui Medicine Co., Ltd.

即将招募 Phase 1 药物

clinicaltrials.gov NCT06549751

MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

适用疾病: Pancreas Cancer；Pancreatic Cancer Metastatic；Pancreatic Cancer (Unresectable)
干预: MT-601 dose 200 million cells，MT-601 dose 400 million cells，MT-601 dose 800 million cells，MT-601 dose 1200 million cells
地点: United States
申办方: Marker Therapeutics, Inc.

正在招募 Phase 1 药物

clinicaltrials.gov NCT04222413

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

适用疾病: Advanced Solid Tumors；Metastatic Pancreatic Cancer；Pediatric Solid Tumor
干预: Metarrestin
地点: United States
申办方: National Cancer Institute (NCI)

即将招募 Phase 2 联合产品

clinicaltrials.gov NCT06991491

Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)

适用疾病: Pancreatic Cancer
干预: GnP in combination with Ivonescimab and SBRT
地点: 未列出
申办方: West China Hospital

正在招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT06943755

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

适用疾病: Pancreatic Neuroendocrine Tumor (pNET)；Extra-Pancreatic Neuroendocrine Tumor (epNET)
干预: Zanzalintinib，Everolimus
地点: United States，Australia，Austria，Belgium 等 11 个
申办方: Exelixis

正在招募 Phase 2 药物

clinicaltrials.gov NCT06313970

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

适用疾病: Pancreatic Cancer
干预: QL1706，Nab-paclitaxel，Gemcitabine，Bevacizumab
地点: China
申办方: Fudan University

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT06782555

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

适用疾病: Metastatic Prostate Cancer；Metastatic Head and Neck Squamous Cell Carcinoma；Metastatic Pancreatic Cancer
干预: Evofosfamide，Zalifrelimab，Balstilimab
地点: United States
申办方: ImmunoGenesis

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07296341

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

适用疾病: Locally Advanced or Metastatic Pancreatic Cancer With
干预: HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine，HRS-4642;nab-paclitaxel; gemcitabine
地点: China
申办方: Shanghai Hengrui Pharmaceutical Co., Ltd.

正在招募 Phase 1, Phase 2 联合产品药物

clinicaltrials.gov NCT03579836

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

适用疾病: Locally Advanced or Metastatic Pancreatic Cancer
干预: BEY1107，Gemcitabine
地点: South Korea
申办方: BeyondBio Inc.

正在招募阶段未标明放疗

clinicaltrials.gov NCT06840067

Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.

适用疾病: Pancreatic Cancer Metastatic；Pancreatic Cancer Non-resectable
干预: carbon ion radiotherapy (CIRT)
地点: China
申办方: Gansu Wuwei Tumor Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT06962267

A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)

适用疾病: Pancreatic Cancer
干预: TQB2916 Injection，Chemotherapy
地点: China
申办方: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

正在招募 Phase 2 药物

clinicaltrials.gov NCT05969171

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer Metastatic
干预: Surufatinib, gemcitabine, nab-paclitaxel，Nab-paclitaxel, gemcitabine
地点: China
申办方: Fudan University

正在招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT07229768

Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors

适用疾病: Pancreatic Cancer
干预: 177Lu-CTR-FAPI
地点: China
申办方: Yan Xing

即将招募 Phase 1 生物制剂

clinicaltrials.gov NCT07587827

Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer

适用疾病: Metastatic Colorectal Cancer (CRC)；Locally Advanced Colorectal Cancer；Metastatic Pancreatic Cancer
干预: Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4)
地点: France
申办方: Centre Georges Francois Leclerc

即将招募 Phase 2 药物

clinicaltrials.gov NCT06621095

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

适用疾病: Pancreatic Cancer；First-line；Metastatic Pancreatic Cancer
干预: anlotinib + benmelstobart + nab-paclitaxel + gemcitabine，nab-paclitaxel + gemcitabine
地点: China
申办方: RenJi Hospital

正在招募 Phase 3 药物

clinicaltrials.gov NCT07066098

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

适用疾病: Pancreatic Cancer
干预: IBI343，Placebo
地点: China
申办方: Innovent Biologics (Suzhou) Co. Ltd.

正在招募 Phase 4 药物手术/操作

clinicaltrials.gov NCT06016855

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

适用疾病: Digestive System Neuroendocrine Tumor G1；Digestive System Neuroendocrine Tumor G2；Metastatic Digestive System Neuroendocrine Neoplasm
干预: Tumor Debulking，Lutetium Lu 177 Dotatate，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: Vanderbilt-Ingram Cancer Center

即将招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT07444541

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

适用疾病: Pancreatic Cancer
干预: ANO31905，ANO31905，Nanoparticle Albumin-Bound Paclitaxel，Gemcitabine
地点: 未列出
申办方: Anova Innovation Limited

正在招募 Phase 2 药物

clinicaltrials.gov NCT05988814

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

适用疾病: Metastatic Pancreatic Cancer
干预: FOLFIRINOX treatment
地点: France
申办方: Centre Georges Francois Leclerc

正在招募 Phase 2 手术/操作

clinicaltrials.gov NCT06690528

Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver

适用疾病: Pancreatic Cancer Metastatic
干预: Surgical resection of both the primary tumor and liver metastases
地点: Italy
申办方: Azienda Ospedaliera di Padova

正在招募 Phase 2 药物

clinicaltrials.gov NCT06662006

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

适用疾病: Advanced Metastatic Pancreatic Cancer
干预: nal-IRI,5-fu,LV, benmelstobart, anlotinib
地点: China
申办方: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

即将招募 Phase 2 药物

clinicaltrials.gov NCT05810792

Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer

适用疾病: Pancreatic Cancer；Surgery；Metastasis
干预: Histamine Dihydrochloride (HDC)，Interleukin-2 (IL-2)
地点: 未列出
申办方: Sahlgrenska University Hospital

正在招募 Phase 2 药物手术/操作

clinicaltrials.gov NCT04858009

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

适用疾病: Metastatic Pancreatic Carcinoma；Stage IV Pancreatic Cancer AJCC v8；Metastatic Malignant Neoplasm in the Peritoneum
干预: Cisplatin，Hyperthermic Intraperitoneal Chemotherapy，Nab-paclitaxel，Computed Tomography
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 药物

clinicaltrials.gov NCT06533332

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

适用疾病: Advanced Solid Tumor；Metastatic Breast Cancer；Metastatic Ovarian Cancer
干预: ERX-315
地点: Australia
申办方: EtiraRx Australia Pty Ltd

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06821048

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

适用疾病: Colorectal Cancer；Stomach Cancer；Pancreatic Cancer
干预: Intraperitoneal infusion of FAST CEA-targeted CAR-T
地点: China
申办方: Weijia Fang, MD

正在招募 Phase 2 药物

clinicaltrials.gov NCT06531278

Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety

适用疾病: Pancreatic Cancer Metastatic to Liver
干预: Irinotecan liposome，Adebrelimab，Oxaliplatin，Fluorouracil
地点: China
申办方: Jiang Long

即将招募 Phase 2, Phase 3 药物

clinicaltrials.gov NCT07656376

Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

适用疾病: Pancreatic Cancer；Pancreatic Carcinoma
干预: DN022150+AG( Stage I ），DN022150+AG（Stage II），placebo+AG（Stage II）
地点: 未列出
申办方: Jiangxi Kvvit Pharmaceutical Co., Ltd.

正在招募 Phase 1 药物

clinicaltrials.gov NCT06500052

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

适用疾病: Esophageal Cancer；Gastric Cancer；Pancreatic Cancer
干预: BL-M17D1
地点: China
申办方: Sichuan Baili Pharmaceutical Co., Ltd.

正在招募 Phase 1 药物手术/操作

clinicaltrials.gov NCT05687123

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

适用疾病: Metastatic Pancreatic Neuroendocrine Tumor；Pancreatic Neoplasm；Stage III Pancreatic Neuroendocrine Tumor AJCC v8
干预: Biospecimen Collection，Computed Tomography，Lutetium Lu 177 Dotatate，Magnetic Resonance Imaging
地点: United States，Canada
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

clinicaltrials.gov NCT06951997

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

适用疾病: Metastatic Pancreatic Cancer
干预: QL1706，Chidamide，Gemcitabine，Nab-paclitaxel
地点: China
申办方: Tianjin Medical University Cancer Institute and Hospital

正在招募 Phase 2 药物

clinicaltrials.gov NCT05040360

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

适用疾病: Metastatic Malignant Neoplasm in the Liver；Pancreatic Neuroendocrine Tumor；Stage I Pancreatic Neuroendocrine Tumor AJCC v8
干预: Capecitabine，Temozolomide
地点: United States，Mexico，Uruguay
申办方: SWOG Cancer Research Network

正在招募 Phase 2 药物

clinicaltrials.gov NCT06914674

Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas

适用疾病: Pancreatic Neoplasms
干预: Tamoxifen 20 mg
地点: China
申办方: Fudan University

正在招募 Phase 1, Phase 2 药物手术/操作

clinicaltrials.gov NCT05053971

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

适用疾病: Advanced Malignant Solid Neoplasm；Locally Advanced Pancreatic Carcinoma；Metastatic Pancreatic Carcinoma
干预: BET Bromodomain Inhibitor ZEN-3694，Computed Tomography，Core Biopsy，Entinostat
地点: United States
申办方: National Cancer Institute (NCI)

即将招募 Phase 2 药物

clinicaltrials.gov NCT07230301

Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions

适用疾病: Pancreatic Cancer Metastatic
干预: Adebrelimab (PD-L1 inhibitor)
地点: 未列出
申办方: Sizhen Wang

即将招募 Phase 4 药物

clinicaltrials.gov NCT06779318

Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis

适用疾病: Pancreatic Cancer；Postoperative Adjuvant Therapy；Maintenance Therapy
干预: S-1
地点: China
申办方: The First Affiliated Hospital with Nanjing Medical University

正在招募阶段未标明器械药物

clinicaltrials.gov NCT06307080

Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis

适用疾病: Pancreatic Cancer
干预: Multi-mode thermal ablation device，Intravenous anti-PD-1 and chemotherapy
地点: China
申办方: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

正在招募 Phase 2 药物

clinicaltrials.gov NCT07110064

QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

适用疾病: Advance Pancreatic Cancer
干预: QL1706+Lenvatinib+AG Regimen
地点: China
申办方: Du Juan

正在招募 Phase 2 生物制剂药物

clinicaltrials.gov NCT01174121

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

适用疾病: Metastatic Colorectal Cancer；Metastatic Pancreatic Cancer；Metastatic Ovarian Cancer
干预: Pembrolizumab (Keytruda)，Fludarabine，Cyclophosphamide，Aldesleukin
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

clinicaltrials.gov NCT03454035

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

适用疾病: Tumor, Solid；Pancreatic Cancer；Melanoma
干预: Ulixertinib，Palbociclib
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

clinicaltrials.gov NCT07410676

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

适用疾病: Cancer；Sarcoma；Leukaemia
干预: EBNK-001 + IL-15 + Pembrolizumab
地点: China
申办方: Essen Biotech

即将招募 Phase 1 生物制剂

clinicaltrials.gov NCT07014878

A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors

适用疾病: Colorectal Cancer；Lung Cancer；Pancreatic Cancer
干预: TCR-T cells
地点: China
申办方: Beijing DCTY Biotech Co.,Ltd.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT07353645

KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer

适用疾病: Colorectal Cancer；Pancreatic Cancer
干预: KRAS Neoantigen Nanovaccine
地点: China
申办方: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

正在招募 EARLY / Phase 1 生物制剂

clinicaltrials.gov NCT05438667

TCR-T Cell Therapy on Advanced Solid Tumors

适用疾病: Pancreatic Cancer
干预: TCR-T therapy
地点: China
申办方: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

正在招募 Phase 1 药物

clinicaltrials.gov NCT06403735

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

适用疾病: Non-small Cell Lung Cancer；Colorectal Cancer；Pancreatic Cancer
干预: QLC1101
地点: China
申办方: Qilu Pharmaceutical Co., Ltd.

正在招募 Phase 2 药物

clinicaltrials.gov NCT07438106

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

适用疾病: Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
干预: HRS-4642 Injection
地点: China
申办方: The First Affiliated Hospital with Nanjing Medical University

即将招募 Phase 3 药物

clinicaltrials.gov NCT07689539

Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

适用疾病: Pancreatic Cancer
干预: DN022150，Chemotherapy
地点: 未列出
申办方: Jiangxi Kvvit Pharmaceutical Co., Ltd.

即将招募 Phase 1 药物

clinicaltrials.gov NCT07650357

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

适用疾病: Advanced Solid Tumor；Non Small Cell Lung Cancer；Pancreatic Carcinoma
干预: CLSP-5282
地点: United States
申办方: Clasp Therapeutics, Inc.

正在招募 Phase 1 生物制剂

clinicaltrials.gov NCT06487377

IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

适用疾病: Pancreatic Cancer；Colorectal Cancer
干预: IX001 TCR-T cells
地点: China
申办方: Shanghai Pudong Hospital

正在招募 Phase 1 生物制剂药物

clinicaltrials.gov NCT06898385

A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

适用疾病: Pancreatic Cancer
干预: IX001 TCR-T injection，Fludarabine，Cyclophosphamide
地点: China
申办方: Sun Yat-sen University

正在招募 Phase 1, Phase 2 生物制剂药物

clinicaltrials.gov NCT03190941

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

适用疾病: Pancreatic Cancer；Gastric Cancer；Gastrointestinal Cancer
干预: Cyclophosphamide，Fludarabine，Anti-KRAS G12V mTCR PBL，Aldesleukin
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 EARLY / Phase 1 药物

clinicaltrials.gov NCT06577532

Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

适用疾病: Pancreatic Neoplasms；Other Solid Tumors
干预: ABO2102，Toripalimab
地点: China
申办方: Ruijin Hospital

正在招募 Phase 1 药物

clinicaltrials.gov NCT07300150

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

适用疾病: Colorectal Cancer；Pancreatic Cancer；Non-Small Cell Lung Cancer
干预: PT0511，Cetuximab
地点: United States，South Korea
申办方: PAQ Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

clinicaltrials.gov NCT04503265

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

适用疾病: Advanced Malignant Neoplasm；Breast Cancer；Ovarian Cancer
干预: AMXI-5001:Dose Escalation Phase I，AMXI-5001:Dose Expansion Phase II
地点: United States
申办方: AtlasMedx, Incorporated

术语	中文意思	对找临床试验有什么用
胰腺导管腺癌 / Pancreatic adenocarcinoma	最常见的胰腺癌病理类型。很多临床试验默认或明确针对这一类型。	搜索胰腺癌试验时，pancreatic adenocarcinoma 往往比 pancreatic cancer 更具体。
转移性胰腺癌 / Metastatic pancreatic cancer	癌症已经扩散到胰腺以外的远处部位，比如肝、腹膜、肺等。	很多试验会限定 metastatic 或 advanced 患者，需要结合影像报告确认。
晚期胰腺癌 / Advanced pancreatic cancer	通常指局部晚期或转移性疾病，具体定义要看试验入组标准。	可以作为 broad keyword 使用，再结合 metastatic、locally advanced 等词细化。
KRAS pancreatic cancer	KRAS 改变在胰腺癌中较常见，不同突变类型可能对应不同研究方向。	可以找 KRAS、KRAS G12D、KRAS G12V、pan-KRAS、RAS pathway 等相关试验。
BRCA pancreatic cancer	BRCA1/BRCA2 突变可能和 DNA 损伤修复通路有关，可能来自遗传或肿瘤检测。	可以找 PARP 抑制剂、DNA damage repair、platinum-sensitive 等相关试验。
FOLFIRINOX	胰腺癌中常见化疗组合之一，既往是否用过会影响部分试验的入组条件。	试验可能要求 previously treated with FOLFIRINOX，或排除不能耐受相关治疗的患者。
Gemcitabine	吉西他滨，是胰腺癌常见治疗药物之一，也常出现在联合治疗方案中。	可以找 gemcitabine-based therapy、after gemcitabine 等相关试验。
Second line	二线治疗，通常指一线治疗失败、进展或不能耐受后更换的下一套方案。	很多胰腺癌试验会限定既往用药和治疗线数，需要准备完整治疗记录。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

胰腺癌

当前同步到的治疗类试验